<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="EN" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Med Chem</journal-id><journal-id journal-id-type="pmc-domain-id">822</journal-id><journal-id journal-id-type="pmc-domain">acssd</journal-id><journal-id journal-id-type="publisher-id">jm</journal-id><journal-title-group><journal-title>Journal of Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">0022-2623</issn><issn pub-type="epub">1520-4804</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>ACS AuthorChoice</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11998014</article-id><article-id pub-id-type="pmcid-ver">PMC11998014.1</article-id><article-id pub-id-type="pmcaid">11998014</article-id><article-id pub-id-type="pmcaiid">11998014</article-id><article-id pub-id-type="pmid">40146185</article-id><article-id pub-id-type="doi">10.1021/acs.jmedchem.5c00340</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group><subject>Article</subject></subj-group></article-categories><title-group><article-title>Application
of Machine Learning and Mechanistic
Modeling to Predict
Intravenous Pharmacokinetic Profiles in Humans</article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9901-9104</contrib-id><name name-style="western"><surname>Jia</surname><given-names initials="X">Xuelian</given-names></name><xref rid="aff1" ref-type="aff">&#8224;</xref><xref rid="aff2" ref-type="aff">&#8225;</xref></contrib><contrib contrib-type="author" id="ath2"><name name-style="western"><surname>Teutonico</surname><given-names initials="D">Donato</given-names></name><xref rid="aff3" ref-type="aff">&#167;</xref></contrib><contrib contrib-type="author" id="ath3"><name name-style="western"><surname>Dhakal</surname><given-names initials="S">Saroj</given-names></name><xref rid="aff4" ref-type="aff">&#8741;</xref></contrib><contrib contrib-type="author" id="ath4"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2540-0505</contrib-id><name name-style="western"><surname>Psarellis</surname><given-names initials="YM">Yorgos M.</given-names></name><xref rid="aff4" ref-type="aff">&#8741;</xref></contrib><contrib contrib-type="author" id="ath5"><name name-style="western"><surname>Abos</surname><given-names initials="A">Alexandra</given-names></name><xref rid="aff5" ref-type="aff">&#8869;</xref></contrib><contrib contrib-type="author" id="ath6"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3559-6129</contrib-id><name name-style="western"><surname>Zhu</surname><given-names initials="H">Hao</given-names></name><xref rid="aff1" ref-type="aff">&#8224;</xref><xref rid="aff2" ref-type="aff">&#8225;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath7"><name name-style="western"><surname>Mavroudis</surname><given-names initials="PD">Panteleimon D.</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff4" ref-type="aff">&#8741;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath8"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3272-0603</contrib-id><name name-style="western"><surname>Pillai</surname><given-names initials="N">Nikhil</given-names></name><xref rid="cor2" ref-type="other">*</xref><xref rid="aff4" ref-type="aff">&#8741;</xref></contrib><aff id="aff1"><label>&#8224;</label>Center
for Biomedical Informatics and Genomics, <institution>Tulane University</institution>, New Orleans, Louisiana 70112, <country>United States</country></aff><aff id="aff2"><label>&#8225;</label>Department
of Chemistry and Biochemistry, <institution>Rowan University</institution>, Glassboro, New Jersey 08028, <country>United States</country></aff><aff id="aff3"><label>&#167;</label>Quantitative
Pharmacology - Pharmacometrics, <institution>Sanofi</institution>, Vitry-sur-Seine 94400, <country>France</country></aff><aff id="aff4"><label>&#8741;</label>Quantitative
Pharmacology - Pharmacometrics, <institution>Sanofi</institution>, Cambridge, Massachusetts 02141, <country>United States</country></aff><aff id="aff5"><label>&#8869;</label>Commercial
Data and Analytics, <institution>Sanofi</institution>, Barcelona 08016, <country>Spain</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Email: <email>panteleimon.mavroudis@sanofi.com</email>.</corresp><corresp id="cor2"><label>*</label>Email: <email>nikhil.pillai@sanofi.com</email>.</corresp></author-notes><pub-date pub-type="epub"><day>27</day><month>03</month><year>2025</year></pub-date><pub-date pub-type="collection"><day>10</day><month>04</month><year>2025</year></pub-date><volume>68</volume><issue>7</issue><issue-id pub-id-type="pmc-issue-id">486639</issue-id><fpage>7737</fpage><lpage>7750</lpage><history><date date-type="received"><day>02</day><month>02</month><year>2025</year></date><date date-type="accepted"><day>20</day><month>03</month><year>2025</year></date><date date-type="rev-recd"><day>14</day><month>03</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>15</day><month>04</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>16</day><month>04</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-04-16 10:25:32.850"><day>16</day><month>04</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Authors</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jm5c00340.pdf"/><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="ab-tgr1" position="float" orientation="portrait" xlink:href="jm5c00340_0011.jpg"/></p><p>Accurate prediction of new compounds&#8217; pharmacokinetic
(PK)
profile in humans is crucial for drug discovery. Traditional methods,
including allometric scaling and mechanistic modeling, rely on parameters
from <italic toggle="yes">in vitro</italic> or <italic toggle="yes">in vivo</italic> testing,
which are labor-intensive and involve ethical concerns. This study
leverages machine learning (ML) to overcome these limitations by developing
data-driven models. We compiled a large data set of small molecules&#8217;
physicochemical and PK properties from public sources and digitized
human plasma concentration&#8211;time profiles for approximately
800 compounds from the literature. We introduced a hybrid modeling
framework that combines ML with physiologically based pharmacokinetic
modeling and a hierarchical ML framework that employs two steps of
learning to directly estimate PK profiles. Tested on 106 drugs, these
frameworks demonstrated prediction accuracies within a 2-fold and
5-fold error for 40&#8211;60% and 80%&#8211;90% of compounds, respectively,
in both AUC and <italic toggle="yes">C</italic><sub>max</sub>. Proposed approaches
could enhance early molecular screening and design, advancing drug
discovery capabilities.</p></abstract><funding-group><award-group><funding-source><institution-wrap><institution>Sanofi</institution><institution-id institution-id-type="doi">10.13039/100004339</institution-id></institution-wrap></funding-source><award-id>NA</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>jm5c00340</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>jm5c00340</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p>Drug discovery is a complex
and time-intensive process that encompasses
several critical stages, including target identification, lead compound
discovery and optimization, and the selection of drug candidates for
advancement into clinical trials.<sup><xref ref-type="bibr" rid="ref1">1</xref>&#8722;<xref ref-type="bibr" rid="ref3">3</xref></sup> Prediction of a new molecule&#8217;s
exposure in humans&#8217; plasma is a critical first step toward
understanding its efficacy and toxicity profile which is crucial for
evaluating its potential as a candidate for further development.<sup><xref ref-type="bibr" rid="ref2">2</xref>,<xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref5">5</xref></sup> Advancing a new molecule to later
stages of drug development before robust estimation of human exposure
can lead to late-stage failures with substantial financial losses.<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> Current approaches for predicting <italic toggle="yes">in
vivo</italic> human PK profiles primarily rely on mathematical models
that build upon the classical foundations of pharmacology such as
in vitro/in vivo extrapolation, noncompartmental analysis (NCA), compartmental
PK modeling, and physiological based PK (PBPK) modeling that involves
a granular representation of human physiology.<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> PBPK model parameters are generally divided into (i) system-specific
parameters that represent physiological properties of the body (e.g.,
blood flows) and are usually based on the organism of interest and
(ii) drug-specific parameters that are related to characteristics
of the drug such as fraction unbound (Fu), p<italic toggle="yes">K</italic><sub>a</sub> acidic/basic, etc. Traditionally, these parameters are experimentally
determined from <italic toggle="yes">in vitro</italic> assays or from <italic toggle="yes">in
vivo</italic> animal PK studies and then scaled to humans. However,
these approaches are time-consuming, labor intensive, and costly,
especially when screening a large number of preclinical compounds.<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> In recent years, significant efforts have been
made to enhance R&amp;D productivity in the pharmaceutical industry,
and computational modeling is now employed throughout drug discovery
to streamline processes, lower experimental costs, and reduce animal
use.<sup><xref ref-type="bibr" rid="ref6">6</xref>&#8722;<xref ref-type="bibr" rid="ref12">12</xref></sup></p><p>Public databases like ChEMBL and PubChem provide extensive
data
on drug properties and activities.<sup><xref ref-type="bibr" rid="ref13">13</xref>,<xref ref-type="bibr" rid="ref14">14</xref></sup> With large
data sets, machine learning (ML) algorithms, which can adapt and learn
patterns, have become an increasingly powerful tool in drug discovery.<sup><xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref15">15</xref>,<xref ref-type="bibr" rid="ref16">16</xref></sup> In particular, it is very common
to predict the property/activity of a molecule by learning the quantitative
structure&#8211;activity relationship (QSAR).<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> With the development of advanced algorithms and chemical
descriptors, QSAR models have become an efficient approach for rapidly
screening a large number of compounds and prioritizing those with
desirable properties and activities. The application of QSAR is particularly
appealing in the initial stages of drug development, where mechanistic
knowledge of how a new molecule distributes and/or is metabolized
in the body and mediates its pharmacological effects is limited. Several
QSAR models have been developed to predict PK parameters such as the
area under the concentration curve (AUC), maximum concentration (<italic toggle="yes">C</italic><sub>max</sub>), Fu, clearance (CL), and steady-state volume
of distribution (VDss).<sup><xref ref-type="bibr" rid="ref18">18</xref>&#8722;<xref ref-type="bibr" rid="ref21">21</xref></sup> Additional studies have also incorporated ML and
mechanistic models to predict PK profiles in rats<sup><xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref22">22</xref>&#8722;<xref ref-type="bibr" rid="ref26">26</xref></sup> and humans.<sup><xref ref-type="bibr" rid="ref27">27</xref>,<xref ref-type="bibr" rid="ref28">28</xref></sup></p><p>Building upon the previous
efforts of our group, in this study,
we developed a hybrid and a hierarchical ML framework to predict human
PK profiles from molecular structures. Both frameworks follow a two-step
modeling process. The hybrid framework combines ML and PBPK modeling,
where ML models are first trained to predict physicochemical (PC)
and PK parameters from chemical structures. These parameters are then
used as inputs for PBPK simulations to predict human PK profiles.
Hierarchical ML organizes tasks in a hierarchical manner to capture
complex relationships.<sup><xref ref-type="bibr" rid="ref29">29</xref></sup> Our hierarchical
ML framework also starts with training QSAR models to predict PK parameters
from chemical structures, as in the first step of the hybrid framework.
In the second step, these predicted parameters are used as features
in a second ML model to predict the PK profiles. To achieve this,
we curated publicly available data on human PK curves and PC/PK parameters,
digitizing PK curves for approximately 800 drugs administered intravenously
(IV). This represents the largest known curated database of human
IV PK profiles for modeling purposes to date. The goal of this study
is to assess whether using ML-derived parameters with PBPK simulations
or standalone ML modeling can generate reasonable human exposure predictions
and demonstrate the feasibility of conducting these predictions for
new drug molecules in the initial stages of drug discovery (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>).</p><fig id="fig1" position="float" orientation="portrait"><label>Figure 1</label><caption><p>Workflow of the study.
Human PK profiles after IV administration
were collected and digitized from the database curated by Lombardo
et al. Various PC and PK parameters were compiled from multiple data
sources, as well. Predictive QSAR models for these PC and PK parameters
were developed after a comprehensive search for optimal combinations
of different ML algorithms and chemical descriptors. For new compounds
lacking experimental parameter values, we can input the SMILES string
to obtain the predicted parameters. These predictions can be used
as the input for PBPK simulation with IV dosing of a 1 mg/kg dose,
representing the hybrid modeling framework. Alternatively, the PC
and PK parameters can be used to train another ML model to directly
predict concentrations at different time points with IV dosing of
1 mg/kg dose, representing the hierarchical ML modeling framework.
PBPK sketch was adapted with permission from ref. (<xref ref-type="bibr" rid="ref4">4</xref>) &#169; 2023 Mavroudis,
Teutonico, Abos and Pillai.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr1" position="float" orientation="portrait" xlink:href="jm5c00340_0001.jpg"/></fig></sec><sec id="sec2"><label>2</label><title>Results and Discussion</title><sec id="sec2.1"><label>2.1</label><title>PK Profiles Overview</title><p>After digitization
of PK curves from the literature, we obtained PK profiles for approximately
800 compounds administered IV. After curation, we obtained PK profiles
for 773 compounds (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>). Among these, 106 compounds that had all of the observed
PC/PK parameter values were used as a test set in both the hybrid
and hierarchical ML frameworks for PK profile prediction. To ensure
an unbiased evaluation, these 106 compounds were excluded from the
training sets used to develop the PC/PK QSAR models. The remaining
667 compounds served as the training set in the hierarchical ML framework.
As shown in <xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>, the training set comprises 8715 concentration values for 667 compounds
at various time points, while the test set includes 1351 concentration
values for 106 compounds.</p><fig id="fig2" position="float" orientation="portrait"><label>Figure 2</label><caption><p>Overlayed IV PK profiles in training set (A)
and test set (B).
IV PK profiles were obtained from digitization of literature mined
PK curves. PK profiles were normalized to 1 mg/kg dose.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr2" position="float" orientation="portrait" xlink:href="jm5c00340_0002.jpg"/></fig><table-wrap id="tbl1" position="float" orientation="portrait"><label>Table 1</label><caption><title>Modeling Set Information for PC/PK
Parameters and Concentrations in PK Profiles</title></caption><table frame="hsides" rules="groups" border="0"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th style="border:none;" align="center" colspan="1" rowspan="1">Parameter</th><th style="border:none;" align="center" colspan="1" rowspan="1">Training set size</th><th style="border:none;" align="center" colspan="1" rowspan="1">Test set size</th><th style="border:none;" align="center" colspan="1" rowspan="1">Unit</th><th style="border:none;" align="center" colspan="1" rowspan="1">Transformation</th></tr></thead><tbody><tr><td style="border:none;" align="left" colspan="1" rowspan="1">Fu</td><td style="border:none;" align="left" colspan="1" rowspan="1">4042</td><td style="border:none;" align="left" colspan="1" rowspan="1">633</td><td style="border:none;" align="left" colspan="1" rowspan="1">&#160;</td><td style="border:none;" align="left" colspan="1" rowspan="1">Log<sub>10</sub></td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">CL</td><td style="border:none;" align="left" colspan="1" rowspan="1">1287</td><td style="border:none;" align="left" colspan="1" rowspan="1">177</td><td style="border:none;" align="left" colspan="1" rowspan="1">L/h/kg</td><td style="border:none;" align="left" colspan="1" rowspan="1">Log<sub>10</sub></td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">VDss</td><td style="border:none;" align="left" colspan="1" rowspan="1">1287</td><td style="border:none;" align="left" colspan="1" rowspan="1">177</td><td style="border:none;" align="left" colspan="1" rowspan="1">L/kg</td><td style="border:none;" align="left" colspan="1" rowspan="1">Log<sub>10</sub></td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">p<italic toggle="yes">K</italic><sub>a</sub> acidic</td><td style="border:none;" align="left" colspan="1" rowspan="1">5306</td><td style="border:none;" align="left" colspan="1" rowspan="1">776</td><td style="border:none;" align="left" colspan="1" rowspan="1">&#160;</td><td style="border:none;" align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">p<italic toggle="yes">K</italic><sub>a</sub> basic</td><td style="border:none;" align="left" colspan="1" rowspan="1">5687</td><td style="border:none;" align="left" colspan="1" rowspan="1">815</td><td style="border:none;" align="left" colspan="1" rowspan="1">&#160;</td><td style="border:none;" align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">Concentration</td><td style="border:none;" align="left" colspan="1" rowspan="1">8715 data points for 667 compounds</td><td style="border:none;" align="left" colspan="1" rowspan="1">1351 data points
for 106 compounds</td><td style="border:none;" align="left" colspan="1" rowspan="1">ng/mL</td><td style="border:none;" align="left" colspan="1" rowspan="1">Log<sub>10</sub></td></tr></tbody></table></table-wrap></sec><sec id="sec2.2"><label>2.2</label><title>PC/PK Parameter Data Sets Overview</title><p>Modeling sets for PC and PK parameters were collected from multiple
sources and varied in size. The number of compounds in the training
and test sets for each PC and PK parameter is listed in <xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>. The distributions of original
PK parameter values were skewed, especially for CL, and VDss (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00340/suppl_file/jm5c00340_si_002.pdf">Figure S1</ext-link>A-C). Therefore, we transformed the
original values into their base-10 logarithms to get closer to normal
distribution for modeling purposes. The distributions of the parameter
values in the training and test sets are shown in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>A&#8211;E. For all PC and
PK parameters, the distribution of values in the test set is within
the range of the training sets.</p><fig id="fig3" position="float" orientation="portrait"><label>Figure 3</label><caption><p>Data distribution of training and test
sets for PC/PK parameters
and PK profiles. (A) Fu values in base-10 logarithm (lg), (B) CL values
in base-10 logarithm, (C) VDss values in base-10 logarithm, (D) p<italic toggle="yes">K</italic><sub>a</sub> acidic, (E) p<italic toggle="yes">K</italic><sub>a</sub> basic, and (F) concentration values in base-10 logarithm at different
time points in PK profiles for compounds in the training and test
sets.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr3" position="float" orientation="portrait" xlink:href="jm5c00340_0003.jpg"/></fig><p>In this study, we used computational p<italic toggle="yes">K</italic><sub>a</sub> and logP values to enable efficient data integration
and evaluation
of the modeling frameworks. While experimental p<italic toggle="yes">K</italic><sub>a</sub> acidic/basic and logP data sets are available in public
databases and literature, their coverage is limited. For example,
the p<italic toggle="yes">K</italic><sub>a</sub> data set from DataWarrior includes
3244 p<italic toggle="yes">K</italic><sub>a</sub> acidic values and 3668 p<italic toggle="yes">K</italic><sub>a</sub> basic values, and a logP data set curated
by Mansouri et al. comprises 4123 compounds.<sup><xref ref-type="bibr" rid="ref30">30</xref>,<xref ref-type="bibr" rid="ref31">31</xref></sup> However, among the 773 drug compounds with curated human PK profiles,
only 29 have either acidic or basic p<italic toggle="yes">K</italic><sub>a</sub> values, and 83 have experimental logP values. This limited overlap
in drug compounds poses challenges for establishing an appropriate
chemical space for QSAR modeling and may lead to inaccuracies in predicting
these values for drug PK profile modeling. In contrast, the ChEMBL
database contains computational p<italic toggle="yes">K</italic><sub>a</sub> values
for a broader range of drugs and drug-like compounds, with &#8764;570
compounds overlapping with the 773 drugs that have human PK profiles.
For compounds in the ChEMBL database with available experimental p<italic toggle="yes">K</italic><sub>a</sub> values, we examined their correlation with
computational p<italic toggle="yes">K</italic><sub>a</sub> values, which demonstrated
reasonable accuracy (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00340/suppl_file/jm5c00340_si_002.pdf">Figure S1</ext-link>D-E). Moreover,
replacing the computational logP values with experimental logP values
for the 83 overlapping compounds did not result in an improvement
in PK profile prediction performance (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00340/suppl_file/jm5c00340_si_002.pdf">Table S2</ext-link>). This outcome may be attributed to the variability in experimental
logP values, which are often measured under different conditions and
setups. Given that many studies on PK profile modeling<sup><xref ref-type="bibr" rid="ref25">25</xref>,<xref ref-type="bibr" rid="ref32">32</xref></sup> and p<italic toggle="yes">K</italic><sub>a</sub> prediction<sup><xref ref-type="bibr" rid="ref33">33</xref>,<xref ref-type="bibr" rid="ref34">34</xref></sup> rely on computationally derived logP and p<italic toggle="yes">K</italic><sub>a</sub> values, we also opted to use computationally derived values
in this study. Moving forward, as more freely available experimental
p<italic toggle="yes">K</italic><sub>a</sub> and logP data for drugs are published,
these data sets can be incorporated into our modeling framework to
enhance predictive accuracy and further validate our models.</p></sec><sec id="sec2.3"><label>2.3</label><title>Predictive QSAR Modeling for PC/PK Parameters</title><p>For each PC/PK parameter, we developed 15 individual QSAR models
using three types of ML algorithms and five types of descriptors.
Each model was trained using a 10-fold cross-validation process, and
its performance was tested on a withheld test set accounting for around
12% of the entire data set. We further developed the consensus model
by averaging predictions from individual QSAR models. The heatmap
in <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref> displays
the <italic toggle="yes">R</italic><sup>2</sup> values for all models on the test
set. The best models, which showed the highest <italic toggle="yes">R</italic><sup>2</sup> and lowest GMFE in predictions, are detailed in <xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>. The scatter plots
in <xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref> illustrate
the correlations between observed and predicted parameter values from
the best models. For Fu, the best model is the SVM algorithm informed
with merged descriptors, which achieved a GMFE of 2-fold and predicted
60% of the test set compounds within a 2-fold error. For CL and VDss,
the consensus model was superior, which achieved GMFE of 2-fold and
1.88-fold, respectively, with 64 and 62% of compounds predicted within
a 2-fold error. The best model for p<italic toggle="yes">K</italic><sub>a</sub> acidic is the XGBoost approach trained with RDKit descriptors, which
achieved GMFE of 1.1-fold and predicted 98% of the test set compounds
within a 2-fold error. The consensus model also proved to be the best
for p<italic toggle="yes">K</italic><sub>a</sub> basic, with a GMFE of 1.26-fold
and 91% of compounds predicted within a 2-fold error.</p><table-wrap id="tbl2" position="float" orientation="portrait"><label>Table 2</label><caption><title>Performance of the Best Models for
PC/PK Parameters and Concentrations in PK Profiles</title></caption><table frame="hsides" rules="groups" border="0"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/></colgroup><thead><tr><th style="border:none;" align="center" colspan="1" rowspan="1">Parameter</th><th style="border:none;" align="center" colspan="1" rowspan="1">Algorithm</th><th style="border:none;" align="center" colspan="1" rowspan="1">Descriptor</th><th style="border:none;" align="center" char="." colspan="1" rowspan="1"><italic toggle="yes">R</italic><sup>2</sup></th><th style="border:none;" align="center" char="." colspan="1" rowspan="1">MAE</th><th style="border:none;" align="center" char="." colspan="1" rowspan="1">RMSE</th><th style="border:none;" align="center" char="." colspan="1" rowspan="1">GMFE<xref rid="tbl2fn1" ref-type="table-fn">a</xref></th><th style="border:none;" align="center" colspan="1" rowspan="1">&lt;2-fold<xref rid="tbl2fn1" ref-type="table-fn">a</xref></th></tr></thead><tbody><tr><td style="border:none;" align="left" colspan="1" rowspan="1">Fu</td><td style="border:none;" align="left" colspan="1" rowspan="1">SVM</td><td style="border:none;" align="left" colspan="1" rowspan="1">Merged</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">0.69</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">0.30</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">0.41</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">2.01</td><td style="border:none;" align="left" colspan="1" rowspan="1">60%</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">CL</td><td style="border:none;" align="left" colspan="1" rowspan="1">Consensus</td><td style="border:none;" align="left" colspan="1" rowspan="1">Consensus</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">0.48</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">0.31</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">0.42</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">2.00</td><td style="border:none;" align="left" colspan="1" rowspan="1">64%</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">VDss</td><td style="border:none;" align="left" colspan="1" rowspan="1">Consensus</td><td style="border:none;" align="left" colspan="1" rowspan="1">Consensus</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">0.60</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">0.28</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">0.35</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">1.88</td><td style="border:none;" align="left" colspan="1" rowspan="1">62%</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">p<italic toggle="yes">K</italic><sub>a</sub> acidic</td><td style="border:none;" align="left" colspan="1" rowspan="1">XGBoost</td><td style="border:none;" align="left" colspan="1" rowspan="1">RDKit</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">0.94</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">0.61</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">1.05</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">1.10</td><td style="border:none;" align="left" colspan="1" rowspan="1">98%</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">p<italic toggle="yes">K</italic><sub>a</sub> basic</td><td style="border:none;" align="left" colspan="1" rowspan="1">Consensus</td><td style="border:none;" align="left" colspan="1" rowspan="1">Consensus</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">0.91</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">0.67</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">0.98</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">1.28</td><td style="border:none;" align="left" colspan="1" rowspan="1">91%</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">Concentration in PK profiles</td><td style="border:none;" align="left" colspan="1" rowspan="1">RF</td><td style="border:none;" align="left" colspan="1" rowspan="1">Fu, CL, VDss, p<italic toggle="yes">K</italic><sub>a</sub>&#160;acidic,&#160;p<italic toggle="yes">K</italic><sub>a</sub>&#160;basic,&#160;time,&#160;infusion&#160;time</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">0.59</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">0.37</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">0.49</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">2.33</td><td style="border:none;" align="left" colspan="1" rowspan="1">55%</td></tr></tbody></table><table-wrap-foot><fn id="tbl2fn1"><label>a</label><p>Calculated after converting predictions
to the original scale, &lt;2-fold: percentage of compounds in test
set with less than 2-fold prediction error.</p></fn></table-wrap-foot></table-wrap><fig id="fig4" position="float" orientation="portrait"><label>Figure 4</label><caption><p>Performance of combinatory QSAR models for PC/PK parameters. The <italic toggle="yes">R</italic><sup>2</sup> values for the test set of each parameter
are shown here.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr4" position="float" orientation="portrait" xlink:href="jm5c00340_0004.jpg"/></fig><fig id="fig5" position="float" orientation="portrait"><label>Figure 5</label><caption><p>Scatter plots of observed and predicted values from the
best model.
(A) Fu values in base-10 logarithms (lg), (B) CL values in base-10
logarithms, (C) VDss values in base-10 logarithms, (D) p<italic toggle="yes">K</italic><sub>a</sub> acidic, (E) p<italic toggle="yes">K</italic><sub>a</sub> basic, and
(F) concentration values in base-10 logarithms at different time points
in PK profiles for compounds in the training and test sets.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr5" position="float" orientation="portrait" xlink:href="jm5c00340_0005.jpg"/></fig><p>As shown in <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>, QSAR models trained using molecular descriptors,
including RDKit,
Mordred, and merged descriptors, generally outperformed those trained
with fingerprints like MACCS and FCFP6. Consensus predictions generated
comparable or even better results than the individual models. The
advantage of the consensus method is that it can mitigate the weaknesses
or biases of single models and enhance predictions across a broader
chemical diversity.<sup><xref ref-type="bibr" rid="ref17">17</xref>,<xref ref-type="bibr" rid="ref35">35</xref>,<xref ref-type="bibr" rid="ref36">36</xref></sup> p<italic toggle="yes">K</italic><sub>a</sub> acidic and basic parameters, which
measure the acidity and basicity of a compound in water solution,
can be accurately predicted because of simple mechanisms. However,
predicting Fu, CL, and VDss remains challenging due to the complex
interactions with proteins, involvement in various biological processes,
and significant interindividual variability in the data. Despite these
challenges, our models achieved an average 2-fold error, comparable
to or better than other published models for the same parameters.<sup><xref ref-type="bibr" rid="ref19">19</xref>&#8722;<xref ref-type="bibr" rid="ref21">21</xref>,<xref ref-type="bibr" rid="ref37">37</xref>,<xref ref-type="bibr" rid="ref38">38</xref></sup> This performance meets common acceptance limits, such as the &#8220;2-fold&#8221;
criterion.<sup><xref ref-type="bibr" rid="ref16">16</xref>,<xref ref-type="bibr" rid="ref39">39</xref></sup></p></sec><sec id="sec2.4"><label>2.4</label><title>Hybrid Modeling Results</title><p>The physiological
parametrization is already available in the PBPK software used in
this modeling exercise (i.e., PK-Sim) while the drug-specific properties
need to be provided typically by the user for each individual drug.
In the hybrid modeling framework, QSAR predicted PC/PK parameters
were used as inputs for PBPK simulations. The required input parameters
are detailed in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00340/suppl_file/jm5c00340_si_002.pdf">Table S3</ext-link>. For the 106 test
set compounds that have all observed PC/PK parameter values and observed
PK profiles, control PBPK simulations were also conducted using the
observed parameters as input. The resulting simulations were compared
to the observed human PK profiles, and AUC and <italic toggle="yes">C</italic><sub>max</sub> fold errors were calculated. We initially utilized the
PK-Sim standard distribution model. As shown in <xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>A, control PBPK simulations achieved more
compounds within a 2-fold error than did the hybrid approach. However,
the hybrid approach demonstrated comparable or even better performance
in the higher fold error range (less than 3-fold and less than 5-fold). <xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig">7</xref></xref> presents several
examples of predicted PK profiles by the hybrid approach and their
comparison with control PBPK simulations using the observed parameters.
The compounds showing well-predicted PK profiles in both the hybrid
approach and control PBPK simulations (<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig">7</xref></xref>A) have accurate predictions of PC/PK parameters
(&lt;2-fold). Compounds with poorly predicted PK profiles compared
to the control typically have inaccurate predictions in Fu and CL.
For example, compound ID 240 exhibited a 41-fold error in CL prediction
(observed: 5.016, predicted: 0.121 L/h/kg), which likely caused a
much higher concentration than the control simulation. Similarly,
compound ID 484, despite good predictions for p<italic toggle="yes">K</italic><sub>a</sub> and Fu, had a 2.46-fold error in CL prediction (observed:
0.84, predicted: 0.34 L/h/kg), leading to a higher AUC of predicted
PK profile using the hybrid approach. Nonetheless, there are cases
where the hybrid approach outperforms the control PBPK simulations.
For instance, compounds with IDs 789 and 1325 showed slightly higher
CL predictions than observed but resulted in more accurate PK profile
predictions. This is likely because ML models can mitigate errors
that may occur due to variability in either recording or performing
the experiment. QSAR predicted and observed PC/PK parameter values
for the 106 test set compounds are provided in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00340/suppl_file/jm5c00340_si_002.pdf">Supporting Information</ext-link>, Data sets. Predicted PK curves for
these compounds are listed in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00340/suppl_file/jm5c00340_si_002.pdf">Figures S2-3</ext-link>.</p><fig id="fig6" position="float" orientation="portrait"><label>Figure 6</label><caption><p>Hybrid modeling performance in predicting PK profiles of 106 test
set compounds. Bar plots show the percentage of compounds in the test
set that have &lt;2-fold, 2- to 3-fold, 3- to 5-fold, and &gt;5-fold
errors in AUC and <italic toggle="yes">C</italic><sub>max</sub> using simulations
from (A) PK-Sim standard (CtrlPBPK_s and hybrid_s) distribution model
or (B) the mean of simulations (CtrlPBPK_m and hybrid_m) from five
different distribution models. Box plots show the distribution of
fold errors in AUC and <italic toggle="yes">C</italic><sub>max</sub> (observed/predicted)
using (C) mean of control PBPK simulations (CtrlPBPK_m) or (D) mean
of hybrid simulations (hybrid_m) from five different distribution
models.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr6" position="float" orientation="portrait" xlink:href="jm5c00340_0006.jpg"/></fig><fig id="fig7" position="float" orientation="portrait"><label>Figure 7</label><caption><p>Example of predicted PK profiles from the hybrid modeling.
hybrid_s
means PK profiles from PBPK simulation using the QSAR predicted parameters
(with PK-Sim distribution model). CtrlPBPK_s means PK profiles from
control PBPK simulation using the observed parameters (with PK-Sim
distribution model). (A) Four compounds represent well predicted PK
profiles from both hybrid_s and CtrlPBPK_s. (B) Four compounds represent
well predicted PK profiles by CtrlPBPK_s but not hybrid_s. (C) Four
compounds represent well predicted PK profiles by hybrid_s but not
CtrlPBPK_s. The identifier shown here is same as that in the Lombardo
data set.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr7" position="float" orientation="portrait" xlink:href="jm5c00340_0007.jpg"/></fig><p>We also explored the influence of different distribution
models,
including the PK-Sim standard,<sup><xref ref-type="bibr" rid="ref40">40</xref></sup> Berezhkovskiy,<sup><xref ref-type="bibr" rid="ref41">41</xref></sup> Poulin and Theil,<sup><xref ref-type="bibr" rid="ref42">42</xref></sup> Rodgers et al.,<sup><xref ref-type="bibr" rid="ref43">43</xref></sup> and Schmidt,<sup><xref ref-type="bibr" rid="ref44">44</xref></sup> on prediction performance. For the 106 test
set compounds, the range of simulations spanned by different distribution
models is provided in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00340/suppl_file/jm5c00340_si_002.pdf">Figures S4-5</ext-link>. In
some cases, such as those with compound IDs 31 and 72, all models
resulted in similar exposure predictions. However, for compounds such
as IDs 315 and 461, the PK profiles showed significant variability
across different distribution models. This is due to the intrinsic
way of how the distribution models were parametrized. For instance,
the Rodgers et al.,<sup><xref ref-type="bibr" rid="ref43">43</xref></sup> and the Schmidt<sup><xref ref-type="bibr" rid="ref44">44</xref></sup> distribution models take into account electrostatic
interactions driven by the drug p<italic toggle="yes">K</italic><sub>a</sub> and
the physiological pH which is not the case for other distribution
models.<sup><xref ref-type="bibr" rid="ref45">45</xref></sup> For this reason, the same PC
parameters of a specific drug may result in different predictions
depending on the distribution model considered. For new compounds
without a clear ADME mechanism, it is challenging to determine which
distribution model is most suitable for each compound. Therefore,
we conducted PBPK simulations using different distribution models
and averaged the results. As shown in <xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>, the mean simulations generally performed
better than, for instance, those using only the PK-Sim standard distribution
model. The hybrid approach with mean simulations predicted 43% of
the AUC and 39% of the <italic toggle="yes">C</italic><sub>max</sub> within a 2-fold
error, and 80% of the AUC and 82% of the <italic toggle="yes">C</italic><sub>max</sub> within a 5-fold error.</p></sec><sec id="sec2.5"><label>2.5</label><title>Hierarchical ML Modeling Results</title><p>The PC/PK parameters and administration route information for 667
compounds were used to train ML models to predict the concentrations
of a compound at different time points (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>). The training was performed using various
combinations of PC/PK parameters as features and two ML algorithms
(performance details are provided in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00340/suppl_file/jm5c00340_si_002.pdf">Table S4</ext-link>). The best-performing model was an RF algorithm, trained with p<italic toggle="yes">K</italic><sub>a</sub> acidic, p<italic toggle="yes">K</italic><sub>a</sub> basic,
Fu, CL, VDss, and infusion time (<xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>). This model achieved an <italic toggle="yes">R</italic><sup>2</sup> of 0.59 and RMSE of 0.49 (ng/mL) on the 106 compounds test set.
The GMFE for predicted concentration values was 2.33, with 55% of
the concentrations falling within a 2-fold error. The concentrations
at different time points for the same compounds were combined to calculate
the AUC and <italic toggle="yes">C</italic><sub>max</sub> values of the curve. <xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig">8</xref></xref> shows the distribution
and percentage of fold errors in AUC and <italic toggle="yes">C</italic><sub>max</sub> values compared to the observed PK profiles for the test set compounds.
60% of the AUC and 59% of the <italic toggle="yes">C</italic><sub>max</sub> were
within a 2-fold error, and 92% of the AUC and 88% of the <italic toggle="yes">C</italic><sub>max</sub> were within a 5-fold error. The mean fold errors for
AUC and <italic toggle="yes">C</italic><sub>max</sub> were 2.3 and 2.75, respectively.
The predicted PK profiles, from both the hybrid simulation and the
hierarchical ML framework, were overlaid with the observed PK profiles
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00340/suppl_file/jm5c00340_si_002.pdf">Figures S4</ext-link>,<xref rid="fig5" ref-type="fig">5</xref>).
Both methods provided reasonable predictions of the PK profiles, with
the hierarchical ML approach showing fewer outliers and slightly better
performance than the hybrid approach (<xref rid="fig6" ref-type="fig">Figures <xref rid="fig6" ref-type="fig">6</xref></xref>, <xref rid="fig8" ref-type="fig">8</xref>, and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00340/suppl_file/jm5c00340_si_002.pdf">Table S5</ext-link>). Specifically, the hierarchical ML
framework achieved lower GMFE for PK profile derived AUC and <italic toggle="yes">C</italic><sub>max</sub>, as well as a higher proportion of compounds
with less than 2-, 3-,5-fold errors in AUC and <italic toggle="yes">C</italic><sub>max</sub> compared to the hybrid approach, indicating improved predictive
reliability. Further analysis of feature importance revealed that
time and CL had the highest importance in predicting concentrations.
VDss also demonstrated relatively high importance, while p<italic toggle="yes">K</italic><sub>a</sub> acidic/basic, infusion time, and Fu exhibited
lower importance scores (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00340/suppl_file/jm5c00340_si_002.pdf">Table S6</ext-link>).</p><fig id="fig8" position="float" orientation="portrait"><label>Figure 8</label><caption><p>Hierarchical
ML modeling performance in predicting PK profiles
of 106 test set compounds. (A) Box plot shows the distribution of
fold errors in AUC and <italic toggle="yes">C</italic><sub>max</sub>. (Observed/predicted)
(B) bar plot shows the percentage of compounds in the test set that
have &lt;2-fold, 2- to 3-fold, 3- to 5-fold, and &gt;5-fold errors
in
AUC and <italic toggle="yes">C</italic><sub>max</sub>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr8" position="float" orientation="portrait" xlink:href="jm5c00340_0008.jpg"/></fig><p>In <xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig">9</xref></xref>, we
present examples of predicted PK profiles from hierarchical ML modeling.
Some compounds, such as IDs 219 and 315, which displayed poor predictions
in both the hybrid approach and control PBPK simulations, were accurately
captured in the hierarchical ML approach (<xref rid="fig9" ref-type="fig">Figures <xref rid="fig9" ref-type="fig">9</xref></xref>B, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00340/suppl_file/jm5c00340_si_002.pdf">S2</ext-link>). This may
be due to missing mechanisms for these compounds (such as transporters,
etc.) in the general PBPK model utilized for this study and/or not
accounting for variability in the populations studied across different
literature sources (e.g., elderly, young, women, men) in the PBPK
model. Effective ML models can generalize better across various drugs
and populations if trained on sufficiently diverse and comprehensive
data sets.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> This ability to generalize
makes them more robust in predicting drug behavior in populations
not previously studied explicitly. While PBPK models may need specific
adjustments for new populations/mechanisms to capture the biological
variability, the hierarchical ML method, based solely on chemical
structures, is particularly useful for the rapid screening of a large
number of compounds, even before their chemical synthesis.<sup><xref ref-type="bibr" rid="ref46">46</xref></sup> The hybrid approach incorporates PBPK simulation
that focuses on the chemical&#8217;s interaction with biological
systems, which can provide interpretable insights into mechanisms
determining the observed PK profiles. Both methods have distinct advantages
and can be effectively combined in practical applications.</p><fig id="fig9" position="float" orientation="portrait"><label>Figure 9</label><caption><p>Example of
the predicted PK profiles from hierarchical ML modeling.
(A) Four compounds represent well predicted PK profiles by both the
hybrid and hierarchical ML approach. (B) Four compounds represent
well predicted PK profiles by hierarchical ML but not hybrid approaches.
(C) Four compounds represent well predicted PK profiles by hybrid
approaches but not hierarchical ML approaches. (D) Four compounds
represent badly predicted PK profiles by both the hybrid and hierarchical
ML approaches. The red line represents the hierarchical ML predicted
PK profile, purple dots are observed PK profiles data, the blue line
represents the mean simulation from hybrid approach, and shaded area
represents the span of simulations from five distribution models.
The identifier shown here is same as that in the Lombardo data set.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr9" position="float" orientation="portrait" xlink:href="jm5c00340_0009.jpg"/></fig><p>Since the hierarchical ML model was developed based
on chemical
structures, predictions for chemicals with structures significantly
different from those in the training set compounds may not be reliable.
We further explored whether implementing an applicability domain (AD)
could improve the performance of the hierarchical ML model. A common
method to define a QSAR model&#8217;s AD involves predicting only
compounds that meet a certain similarity threshold to their nearest
neighbor (NN) in the training set.<sup><xref ref-type="bibr" rid="ref47">47</xref>,<xref ref-type="bibr" rid="ref48">48</xref></sup> For each of
the 106 test set compounds, we calculated the Jaccard and Euclidean
distances to the training sets for predicting different PC/PK parameters.
The NN was defined as the compound with the shortest distance from
the query compound. The distribution of test set compound distances
to the NN across different training sets is detailed in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00340/suppl_file/jm5c00340_si_002.pdf">Figure S6</ext-link>. We further attempted to predict compounds
within AD thresholds using Jaccard similarity values of 0.4 and 0.5,
based on FCFP6 descriptors. Compounds were considered in-AD if their
similarity values to those of NN exceeded the AD threshold across
all training sets. However, we observed no improvement in PK profile
prediction performance for the in-AD compounds (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00340/suppl_file/jm5c00340_si_002.pdf">Figure S7</ext-link>). Implementing AD for the developed model is challenging
because the model involves two steps of learning and the relationship
between structures and PK profiles is not straightforward.</p><p>The
limitation of the current hierarchical ML framework lies in
treating each time point independently without incorporating temporal
relationships between measurements. This approach may result in disjointed
predictions, as observed for compounds such as IDs 789, 1167, and
1210 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00340/suppl_file/jm5c00340_si_002.pdf">Figure S5</ext-link>), where the predicted concentration
at certain time points is underestimated and appears lower than at
subsequent time points. Such discrepancies may also arise from digitization
errors, where the ordering of concentrations for closely spaced time
points is inadvertently reversed, or from natural fluctuations in
the actual PK profiles.</p></sec><sec id="sec2.6"><label>2.6</label><title>External Validation Using Recently Approved
Drugs</title><p>To further validate the predictive performance of both
the hybrid and hierarchical ML modeling approaches, we selected seven
drugs recently approved by the FDA (from 2019 to 2023) and predicted
their IV PK profiles using the developed modeling frameworks. The
observed concentration versus time profiles were digitized from published
literature.<sup><xref ref-type="bibr" rid="ref49">49</xref>&#8722;<xref ref-type="bibr" rid="ref55">55</xref></sup> The digitized PK profiles were normalized to a 1 mg/kg dose for
comparison with the predictions. As shown in <xref rid="fig10" ref-type="fig">Figure <xref rid="fig10" ref-type="fig">10</xref></xref>, the hierarchical ML model reasonably predicted
most of the compounds, with all the compounds predicted within a 4-fold
error and four compounds within a 2-fold error in AUC and <italic toggle="yes">C</italic><sub>max</sub>. The performance of the hybrid approach
was less accurate, especially for Abrocitinib and Gadopiclenol. The
CL for Abrocitinib was underestimated by our QSAR model (observed:
0.722, predicted: 0.240 L/h/kg), resulting in a higher overall concentration
in both modeling frameworks. The CL for gadopiclenol was overestimated
by the QSAR model (observed: 0.079, predicted: 0.243 L/h/kg). This
prediction error resulted in a lower concentration curve in the hierarchical
ML model predictions but not in the hybrid model predictions. One
probable reason is that we were using a base full PBPK model to generate
simulations without accounting for active transporters and other metabolic
information. The accuracy of PK predictions could be further improved
with more high-quality data to enhance the QSAR model for <italic toggle="yes">in vivo</italic> PK parameters, especially CL.</p><fig id="fig10" position="float" orientation="portrait"><label>Figure 10</label><caption><p>PK profiles predictions
of recently approved drugs.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr10" position="float" orientation="portrait" xlink:href="jm5c00340_0010.jpg"/></fig></sec><sec id="sec2.7"><label>2.7</label><title>Comparison with Other PK Prediction Models</title><p>In this study, we curated a large data set of human <italic toggle="yes">in
vivo</italic> concentration&#8211;time profiles (&#8764;800 compounds)
along with PC/PK parameters from public resources to enable PK profile
modeling across diverse drug compounds. The prediction of PK profiles
by combining ML and mechanistic modeling has been explored in a few
recent studies,<sup><xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref25">25</xref>&#8722;<xref ref-type="bibr" rid="ref28">28</xref></sup> and our hybrid modeling framework
has demonstrated a high-throughput approach with comparable performance.
For instance, Geci et al. developed a hybrid modeling approach that
integrated <italic toggle="yes">in silico</italic> predictions of PK parameters
from existing tools with PBPK simulations, achieving 71 and 78% of
AUC and <italic toggle="yes">C</italic><sub>max</sub> predictions, respectively,
within a 5-fold error.<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> Gruber et al.
developed a model that combined deep learning with a surrogate PBPK
model to predict human PK parameters from chemical structures, while
providing concentration&#8211;time profiles for nine examples.<sup><xref ref-type="bibr" rid="ref28">28</xref></sup> In another modeling approach called DeepCt,
rat PK profiles were predicted using a deep learning framework that
incorporates compartmental PK models.<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> For the hierarchical ML modeling framework, conceptually similar
approaches have been reported in the literature for predicting rat
PK profiles.<sup><xref ref-type="bibr" rid="ref22">22</xref>,<xref ref-type="bibr" rid="ref24">24</xref>,<xref ref-type="bibr" rid="ref25">25</xref></sup> To the best of our knowledge, there are currently no published pure
ML frameworks specifically designed for predicting human PK profiles
across a wide range of drugs.</p><p>Regarding the hierarchical ML
modeling framework, although we utilized conventional algorithms,
our approach introduced a novel and practical framework for predicting
concentration&#8211;time PK profiles in humans from chemical structures.
In the second step of the hierarchical ML framework, we trained a
random forest model that predicts concentrations at each time point
independently. Although this approach does not explicitly account
for temporal dependencies, it offers simplicity and robustness for
irregularly sampled data. Time-series deep learning models, such as
recurrent neural networks (RNNs) and neural ordinary differential
equations (Neural-ODEs), can take time&#8211;concentration sequences
as input and generate smooth, continuous predictions.<sup><xref ref-type="bibr" rid="ref56">56</xref></sup> However, RNNs often assume evenly sampled data, which is
uncommon in PK studies, as drug dosing schedules and PK measurements
vary significantly across clinical studies for different drugs.<sup><xref ref-type="bibr" rid="ref57">57</xref></sup> Neural-ODEs, which are neural networks that
model the evolution of hidden states continuously using ODEs, can
handle unevenly sampled data points.<sup><xref ref-type="bibr" rid="ref58">58</xref>,<xref ref-type="bibr" rid="ref59">59</xref></sup> However, like
other deep learning approaches, both Neural-ODEs and RNNs tend to
be computationally intensive, complex to implement, and susceptible
to overfitting, particularly when sample sizes are small. Our study
lays the groundwork for ML modeling and performance evaluation. In
the future, with the collection and curation of more comprehensive
and suitable PK profiles, it will become feasible to more effectively
leverage advanced deep learning techniques such as RNNs and Neural-ODEs,
to further enhance predictive accuracy and model performance.</p></sec></sec><sec id="sec3"><label>3</label><title>Conclusions</title><p>In this study, we developed
a hybrid modeling framework that integrates
ML with mechanistic modeling, alongside a hierarchical ML modeling
framework that involves two step learning to predict human PK profiles
by utilizing chemical structures. Both frameworks achieve reasonable
exposure predictions for most of the drug compounds in the test data
set, with the hierarchical ML modeling framework performing better
than the hybrid approach. The hierarchical ML model, trained on diverse
and comprehensive data, generalizes well across different drugs. Our
work also highlights the benefits of considering multiple distribution
models in the hybrid approach, which provides variability in addition
to a single PK profile estimate. This study utilizes publicly available
human PK studies for a large number of diverse drugs to develop novel
frameworks for predicting human PK profiles. With the ML models presented
here as a starting point, we expect that more advanced ML algorithms
can push the predictive performance even higher. For example, scientific
ML approaches enable the fusion of different information sources for
better predictive performance or system identification from real-world
data (which could in this case lift the dose-linearity assumption).<sup><xref ref-type="bibr" rid="ref60">60</xref>,<xref ref-type="bibr" rid="ref61">61</xref></sup> This effort aims to enable earlier PK profile prediction in the
drug development process and ultimately assist in prioritizing compounds
for future evaluation.</p></sec><sec id="sec4"><label>4</label><title>Experimental Section</title><sec id="sec4.1"><label>4.1</label><title>Human PK Profiles Data</title><p>The database
curated by Lombardo et al. contains PK parameters for 1352 drug compounds
administered IV, which include plasma protein binding (PPB), <italic toggle="yes">in vivo</italic> CL, and VDss.<sup><xref ref-type="bibr" rid="ref62">62</xref></sup> Most
of the corresponding literature provides concentration&#8211;time
plots for the PK studies. After retrieving the available literature,
concentration&#8211;time profiles were digitized from the PK curves
using a digitizer tool developed by Delineate Inc. (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://delineate.pro/">https://delineate.pro/</uri>). This
digitizer, powered by large language modeling (LLM),<sup><xref ref-type="bibr" rid="ref63">63</xref></sup> can automatically identify axes, extract time and concentration
data for each point, and collect dose and unit information, ensuring
efficient data extraction.</p><p>Among the multiple clinical studies,
data measured in healthy adult humans after a single-dose IV administration
were selected. Studies involving coadministration and premedication
with other drugs were removed. The autodigitized PK dynamics data
were manually checked to correct digitization errors (e.g., missing
the first few data points, axis alignment errors, etc.) as well as
errors in dose, time, and concentration. Further preprocessing of
the data involved standardizing the reported human PK data by converting
doses and concentration values into consistent units, using a standard
body weight of 70 kg and a corresponding body surface area of 1.73
m<sup>2</sup>.<sup><xref ref-type="bibr" rid="ref62">62</xref></sup> For compounds tested at
multiple doses, data from doses close to 1 mg/kg were selected. To
facilitate comparison across compounds and align with modeling assumptions,
dose-linearity was assumed for all compounds in the data set, and
all PK profiles were normalized to a 1 mg/kg dose. Additionally, to
ensure data consistency, PK curves for all compounds were overlaid,
and two outliers with exceptionally high concentrations (ID 41: alfentanil<sup><xref ref-type="bibr" rid="ref64">64</xref></sup> and ID 1217: thiopentone)<sup><xref ref-type="bibr" rid="ref65">65</xref></sup> were removed.</p></sec><sec id="sec4.2"><label>4.2</label><title>PC/PK Parameter Data Sets and Curation</title><p>The minimal input properties for small molecule drugs needed for
PBPK modeling include CL, Fu, molecular weight (MW), lipophilicity
(e.g., logP), p<italic toggle="yes">K</italic><sub>a</sub> acidic, p<italic toggle="yes">K</italic><sub>a</sub> basic, and the number of halogens. To increase the modeling
set size of Lombardo et al., we further collected CL and VDss values
from the eDrug3D database.<sup><xref ref-type="bibr" rid="ref66">66</xref></sup> Compounds
in eDrug3D which were already in the Lombardo et al. paper were removed,
and the values from the Lombardo publication were kept. Fu values
were collected from two publicly available data sets: one curated
by Watanabe et al.<sup><xref ref-type="bibr" rid="ref38">38</xref></sup> and another from the
OPERA modeling suite.<sup><xref ref-type="bibr" rid="ref31">31</xref></sup> The p<italic toggle="yes">K</italic><sub>a</sub> acidic and p<italic toggle="yes">K</italic><sub>a</sub> basic data
sets were downloaded from the ChEMBL database.<sup><xref ref-type="bibr" rid="ref14">14</xref></sup> The p<italic toggle="yes">K</italic><sub>a</sub> acidic and p<italic toggle="yes">K</italic><sub>a</sub> basic values in ChEMBL were calculated by
using the ChemAxon software (http://www.chemaxon.com).</p><p>Chemical
structures were represented using SMILES<sup><xref ref-type="bibr" rid="ref67">67</xref></sup> that were retrieved from PubChem web site.<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> Before QSAR modeling, chemical structures were curated and standardized
to enable rigorous model development. In the curation process, salts
were stripped from the molecules, duplicates were removed, and SMILES
strings were converted into their canonical forms and further standardized
by using the MolVS package. The corrected SMILES strings were then
used to calculate the MW, logP, and number of halogens using the RDkit
cheminformatics package version 2024.03.3 (https://www.rdkit.org).
In this study, we focused on the small molecule drugs, so the compounds
with an MW &gt; 900 Da were excluded.</p></sec><sec id="sec4.3"><label>4.3</label><title>Chemical Descriptors and ML Algorithms for
QSAR Modeling</title><p>Five types of descriptors, including chemical
fingerprints and molecular descriptors, were used in this study. Functional
connectivity fingerprints with a diameter of 6 (FCFP6), consisting
of 1024 circular fingerprints, have been used successfully in similarity
search and QSAR modeling.<sup><xref ref-type="bibr" rid="ref68">68</xref></sup> The Molecular
ACCess System (MACCS) keys, consisting of 166 substructure fingerprints,
were also employed.<sup><xref ref-type="bibr" rid="ref69">69</xref></sup> Both types of fingerprints
were calculated using the RDKit package. Additionally, 208 RDKit molecular
descriptors, including topological, compositional, and electrotopological
state descriptors, were also calculated using the RDKit package. Furthermore,
a total of 1613 two-dimensional descriptors were calculated using
the Python package Mordred.<sup><xref ref-type="bibr" rid="ref70">70</xref></sup> Feature selection
was conducted on the training set to remove descriptors with missing
values, those exhibiting low variance (variance &lt;0.2), and one
from any pair of descriptors that were highly correlated with each
other (Pearson correlation &gt;0.85). The number of selected Mordred
descriptors was around 190 for different training sets. We also explored
merging the MACCS, RDKit, and all the Mordred descriptors to take
advantage of the different chemical representations. To prevent overfitting,
the number of descriptors was reduced by removing low variance and
correlated descriptors. The number of selected merged descriptors
was around 270 for different data sets. All the molecular descriptor
values were standardized for compounds in each training set before
model development.</p><p>Three types of ML algorithms were used in
this study: random forest (RF), support vector machine (SVM), and
extreme gradient boosting (XGBoost). RF is an ensemble algorithm that
constructs many randomized decision trees and outputs the mean prediction
of the forest trees to improve the prediction accuracy and avoid overfitting.<sup><xref ref-type="bibr" rid="ref71">71</xref></sup> XGBoost is also an ensemble approach that iteratively
trains an ensemble of shallow decision trees, with each iteration
using the error residuals of the previous model to fit the next model.<sup><xref ref-type="bibr" rid="ref72">72</xref></sup> The SVM regression model aims to find a function
of descriptors-activity space that has a limited deviation (epsilon)
from the actual activity value for all the training data, and at the
same time is as flat as possible to avoid overfitting.<sup><xref ref-type="bibr" rid="ref73">73</xref>,<xref ref-type="bibr" rid="ref74">74</xref></sup> Regression QSAR models for each parameter endpoint were developed
using the combination of one type of descriptor (FCFP6, MACCS, RDKit,
Modred, Merged) and ML algorithm (RF, SVM, XGBoost) and thus resulting
in 15 models for each individual parameter. The consensus QSAR model,
which was generated by averaging predictions from individual models,
was also used in this study.<sup><xref ref-type="bibr" rid="ref17">17</xref>,<xref ref-type="bibr" rid="ref35">35</xref>,<xref ref-type="bibr" rid="ref36">36</xref></sup></p><p>The curated data sets for each parameter (modeling set) were
split
into a training set with approximately 88% of the data and a test
set with the remaining 12% of the data. To prevent potential biases
in model evaluation, we removed compounds from the training set that
share identical descriptors in any of the descriptor sets with those
in the test set. The training set was used to train QSAR models using
the standard 10-fold cross validation (10fcv), while the test set
was reserved for the final evaluation. In the 10fcv procedure, the
training set was split into 10-fold, with 9-fold used to train the
model and the remaining fold used to evaluate the model. This process
was repeated 10 times, such that each fold served as the test set
once. Hyperparameters for building the model (e.g., tree depth in
RF or XGBoost, kernel function for SVM) were tuned using GridSearchCV
using metrics including <italic toggle="yes">R</italic>(<xref ref-type="bibr" rid="ref2">2</xref>) and fold error. Detailed information about the hyperparameters is
presented in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00340/suppl_file/jm5c00340_si_002.pdf">Table S1</ext-link> and can be found
in a previous study.<sup><xref ref-type="bibr" rid="ref75">75</xref></sup></p></sec><sec id="sec4.4"><label>4.4</label><title>PBPK Simulation</title><p>In the hybrid modeling
framework, PC/PK parameter values predicted by the QSAR models were
used as inputs to the PBPK model to simulate concentration&#8211;time
profiles (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>).
PBPK simulations using observed PC/PK parameter values as inputs served
as controls for comparison. PBPK simulations were performed using
a whole-body PBPK model implemented in the PK-Sim software version
11.0<sup>45</sup> (https://www.open-systems-pharmacology.org/). The
model structure and its assumptions are detailed elsewhere.<sup><xref ref-type="bibr" rid="ref76">76</xref></sup> Briefly, this model incorporates multiple compartments
representing organs, which are mathematically connected according
to their physiology. Inputs to the model include drug-specific properties
(e.g., lipophilicity, MW, and Fu) and anatomical and physiological
information (e.g., tissue volumes and blood flow rates), which are
combined to predict the time course of the drug distribution, metabolism,
and excretion in the most relevant organ. Drug-specific properties
are used to predict tissue permeability and partition coefficients
thanks to permeability and distribution models implemented in the
software, which, in turn, are used to predict the drug distribution
across different compartments. Various distribution models have been
developed and are available in PK-Sim to predict drug partition coefficients,
which can sometimes result in different simulations. Since it is not
possible to identify <italic toggle="yes">a priori</italic> the more appropriate
distribution model to describe a specific drug, we explored all five
distribution models available: PK-Sim standard,<sup><xref ref-type="bibr" rid="ref40">40</xref></sup> Berezhkovskiy,<sup><xref ref-type="bibr" rid="ref41">41</xref></sup> Poulin and
Theil,<sup><xref ref-type="bibr" rid="ref42">42</xref></sup> Rodgers et al.,<sup><xref ref-type="bibr" rid="ref43">43</xref></sup> and Schmidt.<sup><xref ref-type="bibr" rid="ref44">44</xref></sup> Detailed descriptions
of these models can be found in the original publications. For each
compound, the PBPK simulations were performed by providing the drug-specific
parameter values and the corresponding route of administration information
(i.e., IV bolus or IV infusion duration in minutes). Simulations were
performed using R version 4.3.2.<sup><xref ref-type="bibr" rid="ref77">77</xref></sup></p></sec><sec id="sec4.5"><label>4.5</label><title>Machine Learning Model to Predict PK Profiles</title><p>In the hierarchical ML framework, the concentration at each time
point was directly predicted from a compound&#8217;s PC/PK parameters
(<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>). These parameters&#8217;
values, derived either from observations or QSAR predictions, were
used to train ML models. A feature selection process was conducted
to evaluate different combinations of features, including CL, VDss,
Fu, p<italic toggle="yes">K</italic><sub>a</sub> acidic, p<italic toggle="yes">K</italic><sub>a</sub> basic, logP, MW, and route of administration information
(i.e., IV bolus or IV infusion duration in minutes) along with time.
The RF and XGBoost algorithms were employed to model the relationship
between these features and the concentration values using the 10fcv
procedure. Further details of the framework as well as its performance
in preclinical species can be seen in prior publication of the group.<sup><xref ref-type="bibr" rid="ref22">22</xref></sup></p></sec><sec id="sec4.6"><label>4.6</label><title>Statistical Analysis</title><p>In this study,
the performance of regression models was evaluated by three commonly
used metrics: coefficient of determination (<italic toggle="yes">R</italic><sup>2</sup>), mean absolute error (MAE), and root mean square error (RMSE),
as represented by <xref rid="eq1" ref-type="disp-formula">eqs <xref rid="eq1" ref-type="disp-formula">1</xref></xref>&#8211;<xref rid="eq3" ref-type="disp-formula">3</xref>, respectively.<disp-formula id="eq1"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="jm5c00340_m001.jpg"/><label>1</label></disp-formula><disp-formula id="eq2"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="jm5c00340_m002.jpg"/><label>2</label></disp-formula><disp-formula id="eq3"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="jm5c00340_m003.jpg"/><label>3</label></disp-formula></p><p>Where <italic toggle="yes">y</italic><sub><italic toggle="yes">i</italic></sub>, <italic toggle="yes">&#375;</italic><sub><italic toggle="yes">i</italic></sub>, and <italic toggle="yes">y&#773;</italic> are the observed, predicted,
and mean observed values of chemicals, respectively. A hold test set
was used to evaluate the generalization ability of the trained models
for each parameter. The model with the highest <italic toggle="yes">R</italic><sup><italic toggle="yes">2</italic></sup> and lowest MAE, RMSE were selected as the
best model for future prediction of new compounds.</p><p>Models for
some PK parameters were developed by using log-transformed
values. To further evaluate the accuracy of the best model for parameter
predictions, we transformed the log predictions back to the original
scale and compared them with the observed values on the original scale
to calculate the geometric mean fold error (GMFE). Additionally, we
also calculated the percentage of compounds predicted within 2-fold,
3-fold, and 5-fold errors compared to the observed true values in
the original scale.<disp-formula id="eq4"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="jm5c00340_m004.jpg"/><label>4</label></disp-formula></p><p>For evaluation of the PK profile prediction,
we calculated the
AUC and <italic toggle="yes">C</italic><sub>max</sub> based on the predicted PK
profile and calculated the AUC and <italic toggle="yes">C</italic><sub>max</sub> fold errors after comparing them with those from the observed PK
profile.</p></sec></sec></body><back><notes id="notes1" notes-type="si"><title>Supporting Information Available</title><p>The Supporting Information is
available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c00340?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c00340</ext-link>.<list id="silist1" list-type="simple"><list-item><p>Curated modeling datasets for PC/PK properties; predicted
and actual properties for 106 test set drugs, hyperparameters for
models, unprocessed source PC/PK properties datasets (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00340/suppl_file/jm5c00340_si_001.xlsx">XLSX</ext-link>)</p></list-item><list-item><p>Supporting
figures and tables (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00340/suppl_file/jm5c00340_si_002.pdf">PDF</ext-link>)</p></list-item></list></p></notes><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sifile1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm5c00340_si_001.xlsx" position="float" orientation="portrait"><caption><p>jm5c00340_si_001.xlsx</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="sifile2" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm5c00340_si_002.pdf" position="float" orientation="portrait"><caption><p>jm5c00340_si_002.pdf</p></caption></media></supplementary-material></sec><notes notes-type="" id="notes2"><title>Author Contributions</title><p>X.J.: methodology,
software, formal analysis, data curation, writing &#8211; original
draft, visualization. D.T.: methodology, software, writing &#8211;
review and editing. S.D.: data curation, writing &#8211; review and
editing. Y.M.P.: data curation, writing &#8211; review and editing.
A.A.: methodology, writing &#8211; review and editing. H.Z.: methodology,
writing&#8211; review and editing. P.D.M.: conceptualization, resources
allocation, methodology, writing&#8211; review and editing. N.P.:
conceptualization, methodology, writing &#8211; review and editing,
supervision.</p></notes><notes notes-type="COI-statement" id="notes3"><p>The authors
declare the following competing financial interest(s): This project
was supported by Sanofi. DT, SD, YMP, AA, PM, NP were employed by
Sanofi during this project and may hold shares and/or Stock options.
XJ was a CO-OP at Sanofi during this project.</p></notes><ack><title>Acknowledgments</title><p>The authors would like to
thank our colleagues,
Dr. Majid Vakilynejad, Dr. Qingping Wang, Dr. Josh Dekeyser, Dr. Aiqun
Li, Dr. Graham Lockwood from Sanofi, for their fruitful discussions
and insightful suggestions. We would also like to thank Emily Nieves
and Jawad Iqbal from Delineate Inc. for establishing LLM-based data
digitization models and enabling clinical PK data retrieval from the
respective publications (https://delineate.pro).</p></ack><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal" id="cit1"><name name-style="western"><surname>Chan</surname><given-names>H. C. S.</given-names></name>; <name name-style="western"><surname>Shan</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Dahoun</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Vogel</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Yuan</surname><given-names>S.</given-names></name><article-title>Advancing
Drug Discovery via Artificial Intelligence</article-title>. <source>Trends Pharmacol. Sci.</source><year>2019</year>, <volume>40</volume> (<issue>10</issue>), <fpage>801</fpage><pub-id pub-id-type="doi">10.1016/j.tips.2019.07.013</pub-id>.<pub-id pub-id-type="pmid">31451243</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal" id="cit2"><name name-style="western"><surname>Davies</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Jones</surname><given-names>R. D. O.</given-names></name>; <name name-style="western"><surname>Grime</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Jansson-Lofmark</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Fretland</surname><given-names>A. J.</given-names></name>; <name name-style="western"><surname>Winiwarter</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Morgan</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>McGinnity</surname><given-names>D. F.</given-names></name><article-title>Improving
the Accuracy of Predicted Human Pharmacokinetics: Lessons Learned
from the AstraZeneca Drug Pipeline Over Two Decades</article-title>. <source>Trends Pharmacol. Sci.</source><year>2020</year>, <volume>41</volume> (<issue>6</issue>), <fpage>390</fpage>&#8211;<lpage>408</lpage>. <pub-id pub-id-type="doi">10.1016/j.tips.2020.03.004</pub-id>.<pub-id pub-id-type="pmid">32359836</pub-id></mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal" id="cit3"><name name-style="western"><surname>Pillai</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Dasgupta</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Sudsakorn</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Fretland</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Mavroudis</surname><given-names>P. D.</given-names></name><article-title>Machine
Learning guided early drug discovery of small molecules</article-title>. <source>Drug Discov. Today</source><year>2022</year>, <volume>27</volume> (<issue>8</issue>), <fpage>2209</fpage>&#8211;<lpage>2215</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2022.03.017</pub-id>.<pub-id pub-id-type="pmid">35364270</pub-id></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name name-style="western"><surname>Mavroudis</surname><given-names>P. D.</given-names></name>; <name name-style="western"><surname>Teutonico</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Abos</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Pillai</surname><given-names>N.</given-names></name><article-title>Application of machine
learning in combination with mechanistic modeling to predict plasma
exposure of small molecules</article-title>. <source>Front. Syst. Biol.</source><year>2023</year>, <volume>3</volume>, <fpage>1180948</fpage><pub-id pub-id-type="doi">10.3389/fsysb.2023.1180948</pub-id>.</mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name name-style="western"><surname>Waring</surname><given-names>M. J.</given-names></name>; <name name-style="western"><surname>Arrowsmith</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Leach</surname><given-names>A. R.</given-names></name>; <name name-style="western"><surname>Leeson</surname><given-names>P. D.</given-names></name>; <name name-style="western"><surname>Mandrell</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Owen</surname><given-names>R. M.</given-names></name>; <name name-style="western"><surname>Pairaudeau</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Pennie</surname><given-names>W. D.</given-names></name>; <name name-style="western"><surname>Pickett</surname><given-names>S. D.</given-names></name>; <name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Wallace</surname><given-names>O.</given-names></name>; <name name-style="western"><surname>Weir</surname><given-names>A.</given-names></name><article-title>An analysis of the
attrition of drug candidates from four major pharmaceutical companies</article-title>. <source>Nat. Rev. Drug Discovery</source><year>2015</year>, <volume>14</volume> (<issue>7</issue>), <fpage>475</fpage>&#8211;<lpage>486</lpage>. <pub-id pub-id-type="doi">10.1038/nrd4609</pub-id>.<pub-id pub-id-type="pmid">26091267</pub-id></mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Ciallella</surname><given-names>H. L.</given-names></name>; <name name-style="western"><surname>Aleksunes</surname><given-names>L. M.</given-names></name>; <name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name><article-title>Advancing computer-aided
drug discovery (CADD) by big data and data-driven machine learning
modeling</article-title>. <source>Drug Discov. Today</source><year>2020</year>, <volume>25</volume> (<issue>9</issue>), <fpage>1624</fpage>&#8211;<lpage>1638</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2020.07.005</pub-id>.<pub-id pub-id-type="pmid">32663517</pub-id><pub-id pub-id-type="pmcid">PMC7572559</pub-id></mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><name name-style="western"><surname>Paul</surname><given-names>S. M.</given-names></name>; <name name-style="western"><surname>Mytelka</surname><given-names>D. S.</given-names></name>; <name name-style="western"><surname>Dunwiddie</surname><given-names>C. T.</given-names></name>; <name name-style="western"><surname>Persinger</surname><given-names>C. C.</given-names></name>; <name name-style="western"><surname>Munos</surname><given-names>B. H.</given-names></name>; <name name-style="western"><surname>Lindborg</surname><given-names>S. R.</given-names></name>; <name name-style="western"><surname>Schacht</surname><given-names>A. L.</given-names></name><article-title>How to
improve R&amp;D
productivity: the pharmaceutical industry&#8217;s grand challenge</article-title>. <source>Nat. Rev. Drug Discovery</source><year>2010</year>, <volume>9</volume> (<issue>3</issue>), <fpage>203</fpage>&#8211;<lpage>214</lpage>. <pub-id pub-id-type="doi">10.1038/nrd3078</pub-id>.<pub-id pub-id-type="pmid">20168317</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name name-style="western"><surname>Morgan</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Brown</surname><given-names>D. G.</given-names></name>; <name name-style="western"><surname>Lennard</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Anderton</surname><given-names>M. J.</given-names></name>; <name name-style="western"><surname>Barrett</surname><given-names>J. C.</given-names></name>; <name name-style="western"><surname>Eriksson</surname><given-names>U.</given-names></name>; <name name-style="western"><surname>Fidock</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Hamren</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Johnson</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>March</surname><given-names>R. E.</given-names></name><article-title>Impact of a five-dimensional
framework on R&amp;D productivity
at AstraZeneca</article-title>. <source>Nat. Rev. Drug Discovery</source><year>2018</year>, <volume>17</volume> (<issue>3</issue>), <fpage>167</fpage>&#8211;<lpage>181</lpage>. <pub-id pub-id-type="doi">10.1038/nrd.2017.244</pub-id>.<pub-id pub-id-type="pmid">29348681</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name name-style="western"><surname>Pammolli</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Righetto</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Abrignani</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Pani</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Pelicci</surname><given-names>P. G.</given-names></name>; <name name-style="western"><surname>Rabosio</surname><given-names>E.</given-names></name><article-title>The endless frontier?
The recent increase of R&amp;D
productivity in pharmaceuticals</article-title>. <source>J. Transl.
Med.</source><year>2020</year>, <volume>18</volume> (<issue>1</issue>), <fpage>162</fpage><pub-id pub-id-type="doi">10.1186/s12967-020-02313-z</pub-id>.<pub-id pub-id-type="pmid">32272953</pub-id><pub-id pub-id-type="pmcid">PMC7147016</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name name-style="western"><surname>Dara</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Dhamercherla</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Jadav</surname><given-names>S. S.</given-names></name>; <name name-style="western"><surname>Babu</surname><given-names>C. M.</given-names></name>; <name name-style="western"><surname>Ahsan</surname><given-names>M. J.</given-names></name><article-title>Machine
Learning in Drug Discovery: A Review</article-title>. <source>Artif.
Intell. Rev.</source><year>2022</year>, <volume>55</volume> (<issue>3</issue>), <fpage>1947</fpage>&#8211;<lpage>1999</lpage>. <pub-id pub-id-type="doi">10.1007/s10462-021-10058-4</pub-id>.<pub-id pub-id-type="pmid">34393317</pub-id><pub-id pub-id-type="pmcid">PMC8356896</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Russo</surname><given-names>D. P.</given-names></name>; <name name-style="western"><surname>Bitounis</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Demokritou</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Jia</surname><given-names>X.</given-names></name>; <name name-style="western"><surname>Huang</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name><article-title>Integrating structure annotation
and machine learning approaches to develop graphene toxicity models</article-title>. <source>Carbon</source><year>2023</year>, <volume>204</volume>, <fpage>484</fpage>&#8211;<lpage>494</lpage>. <pub-id pub-id-type="doi">10.1016/j.carbon.2022.12.065</pub-id>.<pub-id pub-id-type="pmid">36845527</pub-id><pub-id pub-id-type="pmcid">PMC9957041</pub-id></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Russo</surname><given-names>D. P.</given-names></name>; <name name-style="western"><surname>Demokritou</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Jia</surname><given-names>X.</given-names></name>; <name name-style="western"><surname>Huang</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name>; <name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name><article-title>An Online Nanoinformatics
Platform
Empowering Computational Modeling of Nanomaterials by Nanostructure
Annotations and Machine Learning Toolkits</article-title>. <source>Nano
Lett.</source><year>2024</year>, <volume>24</volume>, <fpage>10228</fpage>&#8211;<lpage>10236</lpage>. <pub-id pub-id-type="doi">10.1021/acs.nanolett.4c02568</pub-id>.<pub-id pub-id-type="pmid">39120132</pub-id><pub-id pub-id-type="pmcid">PMC11342361</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Cheng</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Gindulyte</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>He</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>He</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name>; <name name-style="western"><surname>Shoemaker</surname><given-names>B. A.</given-names></name>; <name name-style="western"><surname>Thiessen</surname><given-names>P. A.</given-names></name>; <name name-style="western"><surname>Yu</surname><given-names>B.</given-names></name>; et al. <article-title>PubChem
2023 update</article-title>. <source>Nucleic Acids Res.</source><year>2023</year>, <volume>51</volume> (<issue>D1</issue>), <fpage>D1373</fpage>&#8211;<lpage>D1380</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkac956</pub-id>.<pub-id pub-id-type="pmid">36305812</pub-id><pub-id pub-id-type="pmcid">PMC9825602</pub-id></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name name-style="western"><surname>Zdrazil</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Felix</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Hunter</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Manners</surname><given-names>E. J.</given-names></name>; <name name-style="western"><surname>Blackshaw</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Corbett</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>de Veij</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Ioannidis</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Lopez</surname><given-names>D. M.</given-names></name>; <name name-style="western"><surname>Mosquera</surname><given-names>J. F.</given-names></name>; <name name-style="western"><surname>Magarinos</surname><given-names>M. P.</given-names></name>; <name name-style="western"><surname>Bosc</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Arcila</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Kiziloren</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Gaulton</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Bento</surname><given-names>A. P.</given-names></name>; <name name-style="western"><surname>Adasme</surname><given-names>M. F.</given-names></name>; <name name-style="western"><surname>Monecke</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Landrum</surname><given-names>G. A.</given-names></name>; <name name-style="western"><surname>Leach</surname><given-names>A. R.</given-names></name><article-title>The ChEMBL Database in 2023: a drug
discovery platform spanning multiple bioactivity data types and time
periods</article-title>. <source>Nucleic Acids Res.</source><year>2024</year>, <volume>52</volume> (<issue>D1</issue>), <fpage>D1180</fpage>&#8211;<lpage>D1192</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkad1004</pub-id>.<pub-id pub-id-type="pmid">37933841</pub-id><pub-id pub-id-type="pmcid">PMC10767899</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name name-style="western"><surname>Vamathevan</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Clark</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Czodrowski</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Dunham</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Ferran</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Lee</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Li</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Madabhushi</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Shah</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Spitzer</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Zhao</surname><given-names>S. R.</given-names></name><article-title>Applications
of machine learning in drug discovery
and development</article-title>. <source>Nat. Rev. Drug Discovery</source><year>2019</year>, <volume>18</volume> (<issue>6</issue>), <fpage>463</fpage>&#8211;<lpage>477</lpage>. <pub-id pub-id-type="doi">10.1038/s41573-019-0024-5</pub-id>.<pub-id pub-id-type="pmid">30976107</pub-id><pub-id pub-id-type="pmcid">PMC6552674</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name name-style="western"><surname>Guest</surname><given-names>E. J.</given-names></name>; <name name-style="western"><surname>Aarons</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Houston</surname><given-names>J. B.</given-names></name>; <name name-style="western"><surname>Rostami-Hodjegan</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Galetin</surname><given-names>A.</given-names></name><article-title>Critique of the two-fold measure of prediction success
for ratios: application for the assessment of drug-drug interactions</article-title>. <source>Drug Metab. Dispos.</source><year>2011</year>, <volume>39</volume> (<issue>2</issue>), <fpage>170</fpage>&#8211;<lpage>173</lpage>. <pub-id pub-id-type="doi">10.1124/dmd.110.036103</pub-id>.<pub-id pub-id-type="pmid">21036951</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name name-style="western"><surname>Golbraikh</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Wang</surname><given-names>X. S.</given-names></name>; <name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Tropsha</surname><given-names>A.</given-names></name><article-title>Predictive QSAR modeling:
Methods and applications in drug discovery and chemical risk assessment</article-title>. <source>Handb. Comput. Chem.</source><year>2017</year>, <fpage>2303</fpage>&#8211;<lpage>2340</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-319-27282-5_37</pub-id>.</mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><name name-style="western"><surname>Iwata</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Matsuo</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Mamada</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Motomura</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Matsushita</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Fujiwara</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Maeda</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Handa</surname><given-names>K.</given-names></name><article-title>Predicting total drug
clearance and volumes of distribution using the machine learning-mediated
multimodal method through the imputation of various nonclinical data</article-title>. <source>J. Chem. Inf. Model.</source><year>2022</year>, <volume>62</volume> (<issue>17</issue>), <fpage>4057</fpage>&#8211;<lpage>4065</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.2c00318</pub-id>.<pub-id pub-id-type="pmid">35993595</pub-id><pub-id pub-id-type="pmcid">PMC9472274</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name name-style="western"><surname>Seal</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Trapotsi</surname><given-names>M.-A.</given-names></name>; <name name-style="western"><surname>Subramanian</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>Spjuth</surname><given-names>O.</given-names></name>; <name name-style="western"><surname>Greene</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Bender</surname><given-names>A.</given-names></name><article-title>PKSmart: An Open-Source
Computational Model to Predict
in vivo Pharmacokinetics of Small Molecules</article-title>. <source>bioRxiv</source><year>2024</year>, <pub-id pub-id-type="doi">10.1101/2024.02.02.578658</pub-id>.</mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name name-style="western"><surname>Feinberg</surname><given-names>E. N.</given-names></name>; <name name-style="western"><surname>Joshi</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Pande</surname><given-names>V. S.</given-names></name>; <name name-style="western"><surname>Cheng</surname><given-names>A. C.</given-names></name><article-title>Improvement in ADMET
Prediction with Multitask Deep Featurization</article-title>. <source>J. Med. Chem.</source><year>2020</year>, <volume>63</volume> (<issue>16</issue>), <fpage>8835</fpage>&#8211;<lpage>8848</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b02187</pub-id>.<pub-id pub-id-type="pmid">32286824</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal" id="cit21"><name name-style="western"><surname>Miljkovic</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Martinsson</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Obrezanova</surname><given-names>O.</given-names></name>; <name name-style="western"><surname>Williamson</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Johnson</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Sykes</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Bender</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Greene</surname><given-names>N.</given-names></name><article-title>Machine Learning
Models for Human In Vivo Pharmacokinetic Parameters with In-House
Validation</article-title>. <source>Mol. Pharmaceutics</source><year>2021</year>, <volume>18</volume> (<issue>12</issue>), <fpage>4520</fpage>&#8211;<lpage>4530</lpage>. <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.1c00718</pub-id>.<pub-id pub-id-type="pmid">34758626</pub-id></mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name name-style="western"><surname>Pillai</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Abos</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Teutonico</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Mavroudis</surname><given-names>P. D.</given-names></name><article-title>Machine
learning framework to predict pharmacokinetic profile of small molecule
drugs based on chemical structure</article-title>. <source>Clin Transl
Sci.</source><year>2024</year>, <volume>17</volume> (<issue>5</issue>), <elocation-id>e13824</elocation-id><pub-id pub-id-type="doi">10.1111/cts.13824</pub-id>.<pub-id pub-id-type="pmid">38752574</pub-id><pub-id pub-id-type="pmcid">PMC11097621</pub-id></mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal" id="cit23"><name name-style="western"><surname>Schneckener</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Grimbs</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Hey</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Menz</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Osmers</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Schaper</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Hillisch</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>G&#246;ller</surname><given-names>A. H.</given-names></name><article-title>Prediction
of oral bioavailability in rats: Transferring insights from in vitro
correlations to (deep) machine learning models using in silico model
outputs and chemical structure parameters</article-title>. <source>J.
Chem. Inf. Model.</source><year>2019</year>, <volume>59</volume> (<issue>11</issue>), <fpage>4893</fpage>&#8211;<lpage>4905</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.9b00460</pub-id>.<pub-id pub-id-type="pmid">31714067</pub-id></mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal" id="cit24"><name name-style="western"><surname>Obrezanova</surname><given-names>O.</given-names></name>; <name name-style="western"><surname>Martinsson</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Whitehead</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Mahmoud</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Bender</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Miljkovic</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Grabowski</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Irwin</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Oprisiu</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Conduit</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Segall</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Smith</surname><given-names>G. F.</given-names></name>; <name name-style="western"><surname>Williamson</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Winiwarter</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Greene</surname><given-names>N.</given-names></name><article-title>Prediction Of In Vivo Pharmacokinetic
Paramete<italic toggle="yes">rs</italic>And Time-Exposure Curves In Rats Using
Machine Learning From The Chemical Structure</article-title>. <source>Mol. Pharm.</source><year>2022</year>, <volume>19</volume> (<issue>5</issue>), <fpage>1488</fpage>&#8211;<lpage>1504</lpage>. <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.2c00027</pub-id>.<pub-id pub-id-type="pmid">35412314</pub-id></mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal" id="cit25"><person-group person-group-type="allauthors"><name name-style="western"><surname>Walter</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Aljayyoussi</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Gerner</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Rapp</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Tautermann</surname><given-names>C. S.</given-names></name>; <name name-style="western"><surname>Balazki</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Skalic</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Borghardt</surname><given-names>J. M.</given-names></name>; <name name-style="western"><surname>Humbeck</surname><given-names>L.</given-names></name></person-group><article-title>In
silico PK predictions in
Drug Discovery: Benchmarking of Strategies to Integrate Machine Learning
with Empiric and Mechanistic PK modelling</article-title>, <source>bioRxiv</source>. <pub-id pub-id-type="doi">10.1101/2024.07.30.605777</pub-id>.</mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal" id="cit26"><name name-style="western"><surname>Beckers</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Yonchev</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Desrayaud</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Gerebtzoff</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Rodriguez-Perez</surname><given-names>R.</given-names></name><article-title>DeepCt: Predicting Pharmacokinetic
Concentration-Time
Curves and Compartmental Models from Chemical Structure Using Deep
Learning</article-title>. <source>Mol. Pharmaceutics</source><year>2024</year>, <volume>21</volume> (<issue>12</issue>), <fpage>6220</fpage>&#8211;<lpage>6233</lpage>. <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.4c00562</pub-id>.<pub-id pub-id-type="pmcid">PMC11615940</pub-id><pub-id pub-id-type="pmid">39505357</pub-id></mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal" id="cit27"><name name-style="western"><surname>Geci</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Gadaleta</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>De Lomana</surname><given-names>M. G.</given-names></name>; <name name-style="western"><surname>Ortega-Vallbona</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Colombo</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Serrano-Candelas</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Paini</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Kuepfer</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Schaller</surname><given-names>S.</given-names></name><article-title>Systematic evaluation
of high-throughput PBK modelling
strategies for the prediction of intravenous and oral pharmacokinetics
in humans</article-title>. <source>Arch. Toxicol.</source><year>2024</year>, <volume>98</volume> (<issue>8</issue>), <fpage>2659</fpage>&#8211;<lpage>2676</lpage>. <pub-id pub-id-type="doi">10.1007/s00204-024-03764-9</pub-id>.<pub-id pub-id-type="pmid">38722347</pub-id><pub-id pub-id-type="pmcid">PMC11272695</pub-id></mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal" id="cit28"><name name-style="western"><surname>Gruber</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>F&#252;hrer</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Menz</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Diedam</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>G&#246;ller</surname><given-names>A. H.</given-names></name>; <name name-style="western"><surname>Schneckener</surname><given-names>S.</given-names></name><article-title>Prediction of human pharmacokinetics from chemical
structure: combining mechanistic modeling with machine learning</article-title>. <source>J. Pharm. Sci.</source><year>2024</year>, <volume>113</volume> (<issue>1</issue>), <fpage>55</fpage>&#8211;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/j.xphs.2023.10.035</pub-id>.<pub-id pub-id-type="pmid">39492474</pub-id></mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="book" id="cit29"><person-group person-group-type="allauthors"><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name></person-group><article-title>In
Hierarchical machine learning&#8211;a
learning methodology inspired by human intelligence</article-title>. In <source>International Conference On Rough Sets And Knowledge
Technology</source>; <publisher-name>Springer</publisher-name>, <year>2006</year>; Vol. <volume>4062</volume>, pp. <fpage>28</fpage>&#8211;<lpage>30</lpage>. DOi: <pub-id pub-id-type="doi">10.1007/11795131_3</pub-id>.</mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal" id="cit30"><name name-style="western"><surname>Sander</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Freyss</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>von Korff</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Rufener</surname><given-names>C.</given-names></name><article-title>DataWarrior: an open-source
program for chemistry aware data visualization and analysis</article-title>. <source>J. Chem. Inf. Model.</source><year>2015</year>, <volume>55</volume> (<issue>2</issue>), <fpage>460</fpage>&#8211;<lpage>473</lpage>. <pub-id pub-id-type="doi">10.1021/ci500588j</pub-id>.<pub-id pub-id-type="pmid">25558886</pub-id></mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal" id="cit31"><name name-style="western"><surname>Mansouri</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Grulke</surname><given-names>C. M.</given-names></name>; <name name-style="western"><surname>Judson</surname><given-names>R. S.</given-names></name>; <name name-style="western"><surname>Williams</surname><given-names>A. J.</given-names></name><article-title>OPERA models for
predicting physicochemical properties and environmental fate endpoints</article-title>. <source>J. Cheminf.</source><year>2018</year>, <volume>10</volume> (<issue>1</issue>), <fpage>10</fpage><pub-id pub-id-type="doi">10.1186/s13321-018-0263-1</pub-id>.<pub-id pub-id-type="pmcid">PMC5843579</pub-id><pub-id pub-id-type="pmid">29520515</pub-id></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal" id="cit32"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Du</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Gao</surname><given-names>X.</given-names></name>; <name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Lai</surname><given-names>L.</given-names></name><article-title>A combination of machine learning and PBPK modeling
approach for pharmacokinetics prediction of small molecules in humans</article-title>. <source>Pharm. Res.</source><year>2024</year>, <volume>41</volume> (<issue>7</issue>), <fpage>1369</fpage>&#8211;<lpage>1379</lpage>. <pub-id pub-id-type="doi">10.1007/s11095-024-03725-y</pub-id>.<pub-id pub-id-type="pmid">38918309</pub-id><pub-id pub-id-type="pmcid">PMC11534847</pub-id></mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal" id="cit33"><name name-style="western"><surname>Pan</surname><given-names>X.</given-names></name>; <name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Li</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Zhang</surname><given-names>J. Z. H.</given-names></name>; <name name-style="western"><surname>Ji</surname><given-names>C.</given-names></name><article-title>MolGpka: A
Web Server for Small Molecule pK(a) Prediction Using a Graph-Convolutional
Neural Network</article-title>. <source>J. Chem. Inf. Model.</source><year>2021</year>, <volume>61</volume> (<issue>7</issue>), <fpage>3159</fpage>&#8211;<lpage>3165</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.1c00075</pub-id>.<pub-id pub-id-type="pmid">34251213</pub-id></mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal" id="cit34"><name name-style="western"><surname>Qiu</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Xie</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Gu</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Qi</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Song</surname><given-names>Z.</given-names></name><article-title>Graph transformer based
transfer learning for aqueous pKa prediction
of organic small molecules</article-title>. <source>Chem. Eng. Sci.</source><year>2024</year>, <volume>300</volume>, <fpage>120559</fpage><pub-id pub-id-type="doi">10.1016/j.ces.2024.120559</pub-id>.</mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal" id="cit35"><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name>; <name name-style="western"><surname>Kim</surname><given-names>M. T.</given-names></name>; <name name-style="western"><surname>Sedykh</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name><article-title>Developing Enhanced
Blood-Brain Barrier Permeability Models: Integrating External Bio-Assay
Data in QSAR Modeling</article-title>. <source>Pharm. Res.</source><year>2015</year>, <volume>32</volume> (<issue>9</issue>), <fpage>3055</fpage>&#8211;<lpage>3065</lpage>. <pub-id pub-id-type="doi">10.1007/s11095-015-1687-1</pub-id>.<pub-id pub-id-type="pmid">25862462</pub-id><pub-id pub-id-type="pmcid">PMC4529363</pub-id></mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal" id="cit36"><name name-style="western"><surname>Jia</surname><given-names>X.</given-names></name>; <name name-style="western"><surname>Ciallella</surname><given-names>H. L.</given-names></name>; <name name-style="western"><surname>Russo</surname><given-names>D. P.</given-names></name>; <name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>James</surname><given-names>M. H.</given-names></name>; <name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name><article-title>Construction
of a virtual opioid bioprofile: a data-driven QSAR modeling
study to identify new analgesic opioids</article-title>. <source>ACS
Sustainable Chem. Eng.</source><year>2021</year>, <volume>9</volume> (<issue>10</issue>), <fpage>3909</fpage>&#8211;<lpage>3919</lpage>. <pub-id pub-id-type="doi">10.1021/acssuschemeng.0c09139</pub-id>.<pub-id pub-id-type="pmid">34239782</pub-id><pub-id pub-id-type="pmcid">PMC8259887</pub-id></mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal" id="cit37"><name name-style="western"><surname>Chou</surname><given-names>W. C.</given-names></name>; <name name-style="western"><surname>Lin</surname><given-names>Z.</given-names></name><article-title>Machine learning and
artificial intelligence in physiologically based
pharmacokinetic modeling</article-title>. <source>Toxicol. Sci.</source><year>2023</year>, <volume>191</volume> (<issue>1</issue>), <fpage>1</fpage>&#8211;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1093/toxsci/kfac101</pub-id>.<pub-id pub-id-type="pmid">36156156</pub-id><pub-id pub-id-type="pmcid">PMC9887681</pub-id></mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal" id="cit38"><name name-style="western"><surname>Watanabe</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Esaki</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Kawashima</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Natsume-Kitatani</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Nagao</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Ohashi</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Mizuguchi</surname><given-names>K.</given-names></name><article-title>Predicting
Fraction Unbound in Human Plasma from Chemical Structure: Improved
Accuracy in the Low Value Ranges</article-title>. <source>Mol. Pharmaceutics</source><year>2018</year>, <volume>15</volume> (<issue>11</issue>), <fpage>5302</fpage>&#8211;<lpage>5311</lpage>. <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.8b00785</pub-id>.<pub-id pub-id-type="pmid">30259749</pub-id></mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal" id="cit39"><name name-style="western"><surname>Frechen</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Rostami-Hodjegan</surname><given-names>A.</given-names></name><article-title>Quality Assurance Of PBPK Modeling Platforms And Guidance
On Building, Evaluating, Verifying And Applying PBPK Models Prudently
Under The Umbrella Of Qualification: why, When, What, How And By Whom?</article-title>. <source>Pharm. Res.</source><year>2022</year>, <volume>39</volume> (<issue>8</issue>), <fpage>1733</fpage>&#8211;<lpage>1748</lpage>. <pub-id pub-id-type="doi">10.1007/s11095-022-03250-w</pub-id>.<pub-id pub-id-type="pmid">35445350</pub-id><pub-id pub-id-type="pmcid">PMC9314283</pub-id></mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal" id="cit40"><name name-style="western"><surname>Willmann</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Lippert</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Schmitt</surname><given-names>W.</given-names></name><article-title>From Physicochemistry
To Absorption
And Distribution: predictive Mechanistic Modelling And Computational
Tools</article-title>. <source>Expert. Opin. Drug. Metab. Toxicol.</source><year>2005</year>, <volume>1</volume> (<issue>1</issue>), <fpage>159</fpage>&#8211;<lpage>168</lpage>. <pub-id pub-id-type="doi">10.1517/17425255.1.1.159</pub-id>.<pub-id pub-id-type="pmid">16922658</pub-id></mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal" id="cit41"><name name-style="western"><surname>Berezhkovskiy</surname><given-names>L. M.</given-names></name><article-title>Volume
of distribution at steady state for a linear pharmacokinetic system
with peripheral elimination</article-title>. <source>J. Pharm. Sci.</source><year>2004</year>, <volume>93</volume> (<issue>6</issue>), <fpage>1628</fpage>&#8211;<lpage>1640</lpage>. <pub-id pub-id-type="doi">10.1002/jps.20073</pub-id>.<pub-id pub-id-type="pmid">15124219</pub-id></mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal" id="cit42"><name name-style="western"><surname>Poulin</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Theil</surname><given-names>F. P.</given-names></name><article-title>A priori prediction
of tissue: plasma partition coefficients
of drugs to facilitate the use of physiologically-based pharmacokinetic
models in drug discovery</article-title>. <source>J. Pharm. Sci.</source><year>2000</year>, <volume>89</volume> (<issue>1</issue>), <fpage>16</fpage>&#8211;<lpage>35</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1520-6017(200001)89:1&amp;#x0003c;16::AID-JPS3&amp;#x0003e;3.0.CO;2-E</pub-id>.<pub-id pub-id-type="pmid">10664535</pub-id></mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal" id="cit43"><name name-style="western"><surname>Rodgers</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Leahy</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Rowland</surname><given-names>M.</given-names></name><article-title>Physiologically
based pharmacokinetic
modeling 1: predicting the tissue distribution of moderate-to-strong
bases</article-title>. <source>J. Pharm. Sci.</source><year>2005</year>, <volume>94</volume> (<issue>6</issue>), <fpage>1259</fpage>&#8211;<lpage>1276</lpage>. <pub-id pub-id-type="doi">10.1002/jps.20322</pub-id>.<pub-id pub-id-type="pmid">15858854</pub-id></mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal" id="cit44"><name name-style="western"><surname>Schmitt</surname><given-names>W.</given-names></name><article-title>General approach
for the calculation of tissue to plasma partition coefficients</article-title>. <source>Toxicol. In Vitro</source><year>2008</year>, <volume>22</volume> (<issue>2</issue>), <fpage>457</fpage>&#8211;<lpage>467</lpage>. <pub-id pub-id-type="doi">10.1016/j.tiv.2007.09.010</pub-id>.<pub-id pub-id-type="pmid">17981004</pub-id></mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal" id="cit45"><name name-style="western"><surname>Lippert</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Burghaus</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Edginton</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Frechen</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Karlsson</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Kovar</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Lehr</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Milligan</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Nock</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>Ramusovic</surname><given-names>S.</given-names></name>; et al. <article-title>Open systems pharmacology community&#8212;an
open access, open source, open science approach to modeling and simulation
in pharmaceutical sciences</article-title>. <source>CPT: pharmacometrics
Syst. Pharmacol.</source><year>2019</year>, <volume>8</volume> (<issue>12</issue>), <fpage>878</fpage><pub-id pub-id-type="doi">10.1002/psp4.12473</pub-id>.<pub-id pub-id-type="pmid">31671256</pub-id><pub-id pub-id-type="pmcid">PMC6930856</pub-id></mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal" id="cit46"><name name-style="western"><surname>Bassani</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Parrott</surname><given-names>N. J.</given-names></name>; <name name-style="western"><surname>Manevski</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Zhang</surname><given-names>J. D.</given-names></name><article-title>Another string to
your bow: machine learning prediction of the pharmacokinetic properties
of small molecules</article-title>. <source>Expert Opin. Drug Discovery</source><year>2024</year>, <volume>19</volume> (<issue>6</issue>), <fpage>683</fpage>&#8211;<lpage>698</lpage>. <pub-id pub-id-type="doi">10.1080/17460441.2024.2348157</pub-id>.<pub-id pub-id-type="pmid">38727016</pub-id></mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal" id="cit47"><name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Tropsha</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Fourches</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Varnek</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Papa</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Gramatica</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Oberg</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Dao</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Cherkasov</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Tetko</surname><given-names>I. V.</given-names></name><article-title>Combinatorial QSAR modeling of chemical toxicants tested
against Tetrahymena pyriformis</article-title>. <source>J. Chem. Inf.
Model.</source><year>2008</year>, <volume>48</volume> (<issue>4</issue>), <fpage>766</fpage>&#8211;<lpage>784</lpage>. <pub-id pub-id-type="doi">10.1021/ci700443v</pub-id>.<pub-id pub-id-type="pmid">18311912</pub-id></mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="journal" id="cit48"><name name-style="western"><surname>Ciallella</surname><given-names>H. L.</given-names></name>; <name name-style="western"><surname>Russo</surname><given-names>D. P.</given-names></name>; <name name-style="western"><surname>Aleksunes</surname><given-names>L. M.</given-names></name>; <name name-style="western"><surname>Grimm</surname><given-names>F. A.</given-names></name>; <name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name><article-title>Predictive
modeling of estrogen receptor agonism, antagonism, and binding activities
using machine- and deep-learning approaches</article-title>. <source>Lab. Invest.</source><year>2021</year>, <volume>101</volume> (<issue>4</issue>), <fpage>490</fpage>&#8211;<lpage>502</lpage>. <pub-id pub-id-type="doi">10.1038/s41374-020-00477-2</pub-id>.<pub-id pub-id-type="pmid">32778734</pub-id><pub-id pub-id-type="pmcid">PMC7873171</pub-id></mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="journal" id="cit49"><name name-style="western"><surname>Peeva</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Hodge</surname><given-names>M. R.</given-names></name>; <name name-style="western"><surname>Kieras</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Vazquez</surname><given-names>M. L.</given-names></name>; <name name-style="western"><surname>Goteti</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Tarabar</surname><given-names>S. G.</given-names></name>; <name name-style="western"><surname>Alvey</surname><given-names>C. W.</given-names></name>; <name name-style="western"><surname>Banfield</surname><given-names>C.</given-names></name><article-title>Evaluation
of a Janus
kinase 1 inhibitor, PF-04965842, in healthy subjects: a phase 1, randomized,
placebo-controlled, dose-escalation study</article-title>. <source>Br.
J. Clin. Pharmacol.</source><year>2018</year>, <volume>84</volume> (<issue>8</issue>), <fpage>1776</fpage>&#8211;<lpage>1788</lpage>. <pub-id pub-id-type="doi">10.1111/bcp.13612</pub-id>.<pub-id pub-id-type="pmid">29672897</pub-id><pub-id pub-id-type="pmcid">PMC6046510</pub-id></mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="journal" id="cit50"><name name-style="western"><surname>Hao</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Bourrinet</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Desch&#233;</surname><given-names>P.</given-names></name><article-title>Assessment of pharmacokinetic, pharmacodynamic
profile, and tolerance of gadopiclenol, a new high relaxivity GBCA,
in healthy subjects and patients with brain lesions (phase I/IIa study)</article-title>. <source>Investigat. Radiol.</source><year>2019</year>, <volume>54</volume> (<issue>7</issue>), <fpage>396</fpage>&#8211;<lpage>402</lpage>. <pub-id pub-id-type="doi">10.1097/RLI.0000000000000556</pub-id>.<pub-id pub-id-type="pmid">30870257</pub-id></mixed-citation></ref><ref id="ref51"><mixed-citation publication-type="journal" id="cit51"><name name-style="western"><surname>Wicha</surname><given-names>W. W.</given-names></name>; <name name-style="western"><surname>Prince</surname><given-names>W. T.</given-names></name>; <name name-style="western"><surname>Lell</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Heilmayer</surname><given-names>W.</given-names></name>; <name name-style="western"><surname>Gelone</surname><given-names>S. P.</given-names></name><article-title>Pharmacokinetics and tolerability
of lefamulin following
intravenous and oral dosing</article-title>. <source>J. Antimicrob.
Chemother.</source><year>2019</year>, <volume>74</volume> (<issue>Supplement_3</issue>), <fpage>iii19</fpage>&#8211;<lpage>iii26</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dkz087</pub-id>.<pub-id pub-id-type="pmid">30949704</pub-id><pub-id pub-id-type="pmcid">PMC6449572</pub-id></mixed-citation></ref><ref id="ref52"><mixed-citation publication-type="journal" id="cit52"><name name-style="western"><surname>Cohen-Rabbie</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Vishwanathan</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Wild</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Xu</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Freshwater</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Jain</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Schalkwijk</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Tomkinson</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Zhou</surname><given-names>D.</given-names></name><article-title>Physiologically based pharmacokinetic
modeling for selumetinib to evaluate drug-drug interactions and pediatric
dose regimens</article-title>. <source>J. Clin. Pharmacol.</source><year>2021</year>, <volume>61</volume> (<issue>11</issue>), <fpage>1493</fpage>&#8211;<lpage>1504</lpage>. <pub-id pub-id-type="doi">10.1002/jcph.1935</pub-id>.<pub-id pub-id-type="pmid">34196005</pub-id><pub-id pub-id-type="pmcid">PMC9290801</pub-id></mixed-citation></ref><ref id="ref53"><mixed-citation publication-type="journal" id="cit53"><name name-style="western"><surname>Humeniuk</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Mathias</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Kirby</surname><given-names>B. J.</given-names></name>; <name name-style="western"><surname>Lutz</surname><given-names>J. D.</given-names></name>; <name name-style="western"><surname>Cao</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Osinusi</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Babusis</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Porter</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Wei</surname><given-names>X.</given-names></name>; <name name-style="western"><surname>Ling</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Reddy</surname><given-names>Y. S.</given-names></name>; et al. <article-title>Pharmacokinetic, pharmacodynamic,
and drug-interaction profile of remdesivir, a SARS-CoV-2 replication
inhibitor</article-title>. <source>Clin. Pharmacokinet</source><year>2021</year>, <volume>60</volume> (<issue>5</issue>), <fpage>569</fpage>&#8211;<lpage>583</lpage>. <pub-id pub-id-type="doi">10.1007/s40262-021-00984-5</pub-id>.<pub-id pub-id-type="pmid">33782830</pub-id><pub-id pub-id-type="pmcid">PMC8007387</pub-id></mixed-citation></ref><ref id="ref54"><mixed-citation publication-type="journal" id="cit54"><name name-style="western"><surname>Mahar</surname><given-names>K. M.</given-names></name>; <name name-style="western"><surname>Caltabiano</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Andrews</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Ramanjineyulu</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Young</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Pereira</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Lindsay</surname><given-names>A. C.</given-names></name>; <name name-style="western"><surname>van den Berg</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Cobitz</surname><given-names>A. R.</given-names></name><article-title>Clinical pharmacokinetics of daprodustat:
results of an absorption, distribution, and excretion study with intravenous
microtracer and concomitant oral doses for bioavailability determination</article-title>. <source>Clin. Pharmacol. Drug. Develop.</source><year>2021</year>, <volume>10</volume> (<issue>12</issue>), <fpage>1419</fpage>&#8211;<lpage>1431</lpage>. <pub-id pub-id-type="doi">10.1002/cpdd.1029</pub-id>.<pub-id pub-id-type="pmcid">PMC9298194</pub-id><pub-id pub-id-type="pmid">34713596</pub-id></mixed-citation></ref><ref id="ref55"><mixed-citation publication-type="journal" id="cit55"><name name-style="western"><surname>Gasior</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Husain</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Barra</surname><given-names>M. E.</given-names></name>; <name name-style="western"><surname>Raja</surname><given-names>S. M.</given-names></name>; <name name-style="western"><surname>MacLeod</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Guptill</surname><given-names>J. T.</given-names></name>; <name name-style="western"><surname>Vaitkevicius</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Rybak</surname><given-names>E.</given-names></name><article-title>Intravenous Ganaxolone:
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability in Healthy
Adults</article-title>. <source>Clin. Pharmacol. Drug. Develop.</source><year>2024</year>, <volume>13</volume> (<issue>3</issue>), <fpage>248</fpage>&#8211;<lpage>258</lpage>. <pub-id pub-id-type="doi">10.1002/cpdd.1365</pub-id>.<pub-id pub-id-type="pmid">38231434</pub-id></mixed-citation></ref><ref id="ref56"><mixed-citation publication-type="journal" id="cit56"><name name-style="western"><surname>Ota</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Yamashita</surname><given-names>F.</given-names></name><article-title>Application
of machine learning techniques to the analysis
and prediction of drug pharmacokinetics</article-title>. <source>J.
Controlled Release</source><year>2022</year>, <volume>352</volume>, <fpage>961</fpage>&#8211;<lpage>969</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2022.11.014</pub-id>.<pub-id pub-id-type="pmid">36370876</pub-id></mixed-citation></ref><ref id="ref57"><mixed-citation publication-type="journal" id="cit57"><name name-style="western"><surname>Sherstinsky</surname><given-names>A.</given-names></name><article-title>Fundamentals
of recurrent neural network (RNN) and long short-term memory (LSTM)
network</article-title>. <source>Phys. D: Nonlinear Phenomena</source><year>2020</year>, <volume>404</volume>, <fpage>132306</fpage><pub-id pub-id-type="doi">10.1016/j.physd.2019.132306</pub-id>.</mixed-citation></ref><ref id="ref58"><mixed-citation publication-type="journal" id="cit58"><name name-style="western"><surname>Chen</surname><given-names>R. T. Q.</given-names></name>; <name name-style="western"><surname>Rubanova</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Bettencourt</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Duvenaud</surname><given-names>D.</given-names></name><article-title>Neural ordinary differential
equations</article-title>. <source>arXiv</source><year>2018</year>, <fpage>31</fpage><pub-id pub-id-type="doi">10.48550/arXiv.1806.07366</pub-id>.</mixed-citation></ref><ref id="ref59"><mixed-citation publication-type="journal" id="cit59"><name name-style="western"><surname>Lara-Ben&#237;tez</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Carranza-Garc&#237;a</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Riquelme</surname><given-names>J. C.</given-names></name><article-title>An experimental
review on deep learning architectures for time series forecasting</article-title>. <source>Int. J. Neur. Syst.</source><year>2021</year>, <volume>31</volume> (<issue>3</issue>), <fpage>2130001</fpage><pub-id pub-id-type="doi">10.1142/S0129065721300011</pub-id>.<pub-id pub-id-type="pmid">33588711</pub-id></mixed-citation></ref><ref id="ref60"><mixed-citation publication-type="journal" id="cit60"><name name-style="western"><surname>Lu</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Deng</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name>; <name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Guan</surname><given-names>Y.</given-names></name><article-title>Neural-ODE
for pharmacokinetics modeling and its advantage to alternative machine
learning models in predicting new dosing regimens</article-title>. <source>iScience</source><year>2021</year>, <volume>24</volume>, <fpage>102804</fpage><pub-id pub-id-type="doi">10.1016/j.isci.2021.102804</pub-id>.<pub-id pub-id-type="pmid">34308294</pub-id><pub-id pub-id-type="pmcid">PMC8283337</pub-id></mixed-citation></ref><ref id="ref61"><mixed-citation publication-type="journal" id="cit61"><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Psarellis</surname><given-names>Y. M.</given-names></name>; <name name-style="western"><surname>Siettos</surname><given-names>C. I.</given-names></name>; <name name-style="western"><surname>Kevrekidis</surname><given-names>I. G.</given-names></name><article-title>Learning
black-and gray-box chemotactic PDEs/closures from agent based Monte
Carlo simulation data</article-title>. <source>J. Math. Biol.</source><year>2023</year>, <volume>87</volume> (<issue>1</issue>), <fpage>15</fpage><pub-id pub-id-type="doi">10.1007/s00285-023-01946-0</pub-id>.<pub-id pub-id-type="pmid">37341784</pub-id></mixed-citation></ref><ref id="ref62"><mixed-citation publication-type="journal" id="cit62"><name name-style="western"><surname>Lombardo</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Berellini</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Obach</surname><given-names>R. S.</given-names></name><article-title>Trend Analysis of a Database of Intravenous
Pharmacokinetic Parameters in Humans for 1352 Drug Compounds</article-title>. <source>Drug Metab. Dispos.</source><year>2018</year>, <volume>46</volume> (<issue>11</issue>), <fpage>1466</fpage>&#8211;<lpage>1477</lpage>. <pub-id pub-id-type="doi">10.1124/dmd.118.082966</pub-id>.<pub-id pub-id-type="pmid">30115648</pub-id></mixed-citation></ref><ref id="ref63"><mixed-citation publication-type="journal" id="cit63"><name name-style="western"><surname>DeSmet</surname><given-names>C.C</given-names></name>; <name name-style="western"><surname>Cook</surname><given-names>D. J.</given-names></name><article-title>HydraGAN: A Cooperative
Agent Model for Multi-Objective
Data Generation</article-title>. <source>ACM Trans. Intell. Syst. Technol.</source><year>2024</year>, <volume>15</volume> (<issue>3</issue>), <fpage>1</fpage>&#8211;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1145/3653982</pub-id>.<pub-id pub-id-type="pmcid">PMC11513586</pub-id><pub-id pub-id-type="pmid">39469108</pub-id></mixed-citation></ref><ref id="ref64"><mixed-citation publication-type="journal" id="cit64"><name name-style="western"><surname>Bower</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Hull</surname><given-names>C. J.</given-names></name><article-title>Comparative pharmacokinetics
of fentanyl and alfentanil</article-title>. <source>Br. J. Anaesth</source><year>1982</year>, <volume>54</volume> (<issue>8</issue>), <fpage>871</fpage>&#8211;<lpage>877</lpage>. <pub-id pub-id-type="doi">10.1093/bja/54.8.871</pub-id>.<pub-id pub-id-type="pmid">6125162</pub-id></mixed-citation></ref><ref id="ref65"><mixed-citation publication-type="journal" id="cit65"><name name-style="western"><surname>Cordato</surname><given-names>D. J.</given-names></name>; <name name-style="western"><surname>Gross</surname><given-names>A. S.</given-names></name>; <name name-style="western"><surname>Herkes</surname><given-names>G. K.</given-names></name>; <name name-style="western"><surname>Mather</surname><given-names>L. E.</given-names></name><article-title>Pharmacokinetics
of thiopentone enantiomers following intravenous injection or prolonged
infusion of rac-thiopentone</article-title>. <source>Br. J. Clin. Pharmacol.</source><year>1997</year>, <volume>43</volume> (<issue>4</issue>), <fpage>355</fpage>&#8211;<lpage>362</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-2125.1997.00567.x</pub-id>.<pub-id pub-id-type="pmid">9146846</pub-id><pub-id pub-id-type="pmcid">PMC2042768</pub-id></mixed-citation></ref><ref id="ref66"><mixed-citation publication-type="journal" id="cit66"><name name-style="western"><surname>Pihan</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Colliandre</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Guichou</surname><given-names>J. F.</given-names></name>; <name name-style="western"><surname>Douguet</surname><given-names>D.</given-names></name><article-title>e-Drug3D: 3D structure
collections dedicated to drug repurposing and fragment-based drug
design</article-title>. <source>Bioinformatics</source><year>2012</year>, <volume>28</volume> (<issue>11</issue>), <fpage>1540</fpage>&#8211;<lpage>1541</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/bts186</pub-id>.<pub-id pub-id-type="pmid">22539672</pub-id></mixed-citation></ref><ref id="ref67"><mixed-citation publication-type="journal" id="cit67"><name name-style="western"><surname>Weininger</surname><given-names>D.</given-names></name><article-title>SMILES, a
chemical language and information system. 1. Introduction to methodology
and encoding rules</article-title>. <source>J. Chem. Inf. Comput. Sci.</source><year>1988</year>, <volume>28</volume> (<issue>1</issue>), <fpage>31</fpage>&#8211;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1021/ci00057a005</pub-id>.</mixed-citation></ref><ref id="ref68"><mixed-citation publication-type="journal" id="cit68"><name name-style="western"><surname>Rogers</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Hahn</surname><given-names>M.</given-names></name><article-title>Extended-connectivity fingerprints</article-title>. <source>J. Chem.
Inf. Model.</source><year>2010</year>, <volume>50</volume> (<issue>5</issue>), <fpage>742</fpage>&#8211;<lpage>754</lpage>. <pub-id pub-id-type="doi">10.1021/ci100050t</pub-id>.<pub-id pub-id-type="pmid">20426451</pub-id></mixed-citation></ref><ref id="ref69"><mixed-citation publication-type="journal" id="cit69"><name name-style="western"><surname>Durant</surname><given-names>J. L.</given-names></name>; <name name-style="western"><surname>Leland</surname><given-names>B. A.</given-names></name>; <name name-style="western"><surname>Henry</surname><given-names>D. R.</given-names></name>; <name name-style="western"><surname>Nourse</surname><given-names>J. G.</given-names></name><article-title>Reoptimization of
MDL keys for use in drug discovery</article-title>. <source>J. Chem.
Inf. Comput. Sci.</source><year>2002</year>, <volume>42</volume> (<issue>6</issue>), <fpage>1273</fpage>&#8211;<lpage>1280</lpage>. <pub-id pub-id-type="doi">10.1021/ci010132r</pub-id>.<pub-id pub-id-type="pmid">12444722</pub-id></mixed-citation></ref><ref id="ref70"><mixed-citation publication-type="journal" id="cit70"><name name-style="western"><surname>Moriwaki</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Tian</surname><given-names>Y. S.</given-names></name>; <name name-style="western"><surname>Kawashita</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Takagi</surname><given-names>T.</given-names></name><article-title>Mordred: a molecular
descriptor calculator</article-title>. <source>J. Cheminf.</source><year>2018</year>, <volume>10</volume> (<issue>1</issue>), <fpage>4</fpage><pub-id pub-id-type="doi">10.1186/s13321-018-0258-y</pub-id>.<pub-id pub-id-type="pmcid">PMC5801138</pub-id><pub-id pub-id-type="pmid">29411163</pub-id></mixed-citation></ref><ref id="ref71"><mixed-citation publication-type="journal" id="cit71"><name name-style="western"><surname>Breiman</surname><given-names>L.</given-names></name><article-title>Random forests</article-title>. <source>Mach. Learn.</source><year>2001</year>, <volume>45</volume>, <fpage>5</fpage>&#8211;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1023/A:1010933404324</pub-id>.</mixed-citation></ref><ref id="ref72"><mixed-citation publication-type="book" id="cit72"><person-group person-group-type="allauthors"><name name-style="western"><surname>Chen</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Guestrin</surname><given-names>C.</given-names></name></person-group><article-title>In Xgboost: A scalable
tree boosting system</article-title>. In <source>Proceedings Of The
22nd ACM SIGKDD International Conference On Knowledge Discovery And
Data Mining</source>; <publisher-name>ACM Digital Library</publisher-name>, <year>2016</year>; pp. <fpage>785</fpage>&#8211;<lpage>794</lpage>. DOI: <pub-id pub-id-type="doi">10.1145/2939672.2939785</pub-id>.</mixed-citation></ref><ref id="ref73"><mixed-citation publication-type="book" id="cit73"><person-group person-group-type="allauthors"><name name-style="western"><surname>Awad</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Khanna</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Awad</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Khanna</surname><given-names>R.</given-names></name></person-group><article-title>Support Vector
Regression</article-title>. In <source>Efficient Learning Machines:
theories, Concepts, And
Applications For Engineers And System Designers</source>; <publisher-name>Springer</publisher-name>, <year>2015</year>; pp. <fpage>67</fpage>&#8211;<lpage>80</lpage>.</mixed-citation></ref><ref id="ref74"><mixed-citation publication-type="journal" id="cit74"><name name-style="western"><surname>Smola</surname><given-names>A. J.</given-names></name>; <name name-style="western"><surname>Sch&#246;lkopf</surname><given-names>B.</given-names></name><article-title>A tutorial
on support vector regression</article-title>. <source>Statist. Comput.</source><year>2004</year>, <volume>14</volume>, <fpage>199</fpage>&#8211;<lpage>222</lpage>. <pub-id pub-id-type="doi">10.1023/B:STCO.0000035301.49549.88</pub-id>.</mixed-citation></ref><ref id="ref75"><mixed-citation publication-type="book" id="cit75"><person-group person-group-type="allauthors"><name name-style="western"><surname>Ciallella</surname><given-names>H. L.</given-names></name>; <name name-style="western"><surname>Chung</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Russo</surname><given-names>D.
P.</given-names></name>; <name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name></person-group><article-title>Automatic Quantitative Structure&#8211;Activity
Relationship Modeling to Fill Data Gaps in High-Throughput Screening</article-title>. In <source>High-Throughput Screening Assays in Toxicology</source>; <publisher-name>Springer</publisher-name>, <year>2022</year>; pp. <fpage>169</fpage>&#8211;<lpage>187</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-0716-2213-1_16</pub-id><pub-id pub-id-type="pmid">35294765</pub-id></mixed-citation></ref><ref id="ref76"><mixed-citation publication-type="journal" id="cit76"><name name-style="western"><surname>Kuepfer</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Niederalt</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Wendl</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Schlender</surname><given-names>J. F.</given-names></name>; <name name-style="western"><surname>Willmann</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Lippert</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Block</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Eissing</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Teutonico</surname><given-names>D.</given-names></name><article-title>Applied concepts in PBPK modeling: how to build a PBPK/PD
model</article-title>. <source>CPT: pharm. Syst. Pharmacol.</source><year>2016</year>, <volume>5</volume> (<issue>10</issue>), <fpage>516</fpage>&#8211;<lpage>531</lpage>. <pub-id pub-id-type="doi">10.1002/psp4.12134</pub-id>.<pub-id pub-id-type="pmcid">PMC5080648</pub-id><pub-id pub-id-type="pmid">27653238</pub-id></mixed-citation></ref><ref id="ref77"><mixed-citation publication-type="computer-program" id="cit77"><collab>R Foundation for
Statistical Computing</collab>, <source>Team R: a language and environment
for statistical computing</source>; <publisher-name>R Foundation for
Statistical Computing</publisher-name>: <publisher-loc>Vienna, Austria</publisher-loc>, <year>2022</year>.</mixed-citation></ref></ref-list></back></article></pmc-articleset>